Prefusion-stabilized RSV f protein ectodomains
Engineered RSV F proteins with mutations and trimerization domains enhance thermostability and expression, addressing stability issues in RSV vaccines and improving immunogenicity for effective RSV vaccine and diagnostic applications.
Patent Information
- Application Number
- PCT/US2026/027314
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing RSV vaccines face challenges with prefusion-stabilized RSV F protein thermostability and expression, limiting their effectiveness as immunogens.
Engineered RSV F proteins with specific amino acid mutations and trimerization domains maintain the prefusion conformation, enhancing thermostability and expression, and are designed to bind prefusion-specific antibodies.
The engineered proteins improve immunogenicity and stability, enabling effective vaccine formulations and diagnostic assays for RSV-specific immune responses.
Smart Images

Figure IMGF000009_0001_TABLE 
Figure IMGF000010_0001_TABLE 
Figure IMGF000011_0001_TABLE
Abstract
Description
DESCRIPTIONPREFUSION-STABILIZED RSV F PROTEIN ECTODOMAINSREFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the priority benefit of United States provisional application number 63 / 803,186, filed May 9, 2025, the entire contents of which are incorporated herein by reference.REFERENCE TO A SEQUENCE LISTING
[0002] This application contains a sequence listing xml, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said xml sequence listing, created on May 8, 2026, is named UTFBP1396WO.xml and is 188,935 bytes in size.BACKGROUND1. Field
[0003] The present disclosure relates generally to the fields of medicine, virology, immunology, and protein engineering. More particularly, it concerns engineered Respiratory Syncytial Virus (RSV) fusion (F) protein polypeptides and uses thereof.2. Description of Related Art
[0004] Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections in infants, young children, and older adults, often resulting in severe illness, such as bronchiolitis and pneumonia. The RSV fusion (F) protein plays a critical role in the virus’s ability to infect cells and is a target for neutralizing antibodies. However, the F protein undergoes a structural transition from its prefusion to postfusion conformation, which reduces its effectiveness as an immunogen. RSV vaccines, such as Arexvy and Abrysvo, rely on a prefusion-stabilized RSV F protein to generate immunity. However, improvements in prefusion-stabilized RSV F protein thermostability and expression are still needed.SUMMARY
[0005] As such, provided herein are engineered proteins having at least one amino acid mutation relative to the amino acid sequence of a native RSV F protein. The mutations enhance both the expression yield and thermostability of the prefusion form of the protein. As such, the14900-4270-2501 , v. 1engineered proteins may be stabilized in the prefusion conformation of RS V F. The engineered proteins may specifically bind to an RSV F prefusion-specific antibody.
[0006] Provided herein are engineered proteins comprising an engineered Respiratory Syncytial Virus (RSV) Fusion (F) protein ectodomain comprising a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 26-513 of SEQ ID NO: 1 or 55, said engineered protein comprising at least one substitution at a position selected from the group consisting of: A412; D440; E60; 1148; 179; K191; K465; L203; L230; N240; N345; N388; N460; Q210; Q283; Q284; Q302; Q354; Q361; Q494; R229; R364; S190; S350; S398; S405; S425; S46; T189; T234; T244; T323; T58: V154; V192; V482; Y306; and any of the positions listed in Tables 1 or 2, wherein the positions are relative to SEQ ID NO: 1 or 55. The engineered protein may comprise at least one substitution selected from the group consisting of: A412F; A412I; A412T; D440A; D440H; E60F; I148T; I79W; K191I; K191V; K465P; L203F; L230F; N240W; N240Y; N345V; N388S; N460P; Q210V; Q283A; Q284F; Q284W; Q302I; Q302V; Q354D; Q361I; Q494R; R229I; R364F; R364W; R364Y; S190F; S190L; S190W; S190Y; S350L; S398F; S405I; S405L; S405V; S425F; S425L; S425W; S46L; T189V; T234A; T234I; T244V; T323L; T58L; V154L; V192T; V482L; Y306P; and any of the substitutions listed in Tables 1 or 2, wherein the positions are relative to SEQ ID NO: 1 or 55. The engineered protein may lack the cytoplasmic tail of RSV F. The RSV F protein ectodomain may comprise an elimination of the furin cleavage site.
[0007] The engineered protein may comprise at least one set of substitutions selected from the following sets: (a) T244V, Q284F, and N345V: (b) K75C, S215C, Q279P, T335I, and N437P; (c) K75C, S215C, Q279P, T335I, N345V, and N437P; (d) K75C, S215C, Q279P, N345V, and N437P; (e) K75C, S215C, Q270E, Q279P, N345V, and N437P; (f) Q270E, Q279P. N345V, and N437P; (g) K75C, S215C, N165D, Q279P. N345V, and N437P; (h) K75C, S215C, K80F, Q279P, and Q361I; (i) K75C. S215C, Q279P, and N437P; (j) K80F, N197D, Q270E, Q279P, N345V, and N437P; (k) K75C, S215C, Q279P, and Q361I; (1) K75C, S215C, A170C, A177C, Q279P, R364Y, and N437P; (m) K80F, Q270E, Q279P, N345V, and N437P; (n) K75C, S215C, Q279P, and N345V; (o) K75C, S215C, K80F, Q279P, and N345V; (p) K75C, S215C, Q270E, Q279P, and N345V; (q) A147P, Q279P, and S443P; (r) K375C, S215C, N345V, N388S, S405V; (s) K80F, N197D. Q270E, N345V; (t) any of the sets of24900-4270-2501 , v. 1substitutions listed in Table 1; and (u) any combination of substitutions listed in Table 2, wherein the positions are relative to SEQ ID NO: 1 or 55.
[0008] The RSV F protein ectodomain may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to amino acids 26-513 of any one of SEQ ID NOs: 3-28.
[0009] The engineered RSV F protein ectodomain may be fused or conjugated to a trimerization domain. The trimerization domain may comprise a T4 fibritin trimerization domain; a GCN4 domain; a 4J4A domain; a two-helix bundle comprising complementary first heptad repeat (HR1) and second heptad repeat (HR2) regions; or a combination thereof. The trimerization domain may be fused to the C-terminus of the ectodomain via a linker. The linker may comprise the sequence of Gly-Ser. The linker may comprise the sequence of amino acid positions 514-517 of SEQ ID NO: 2.
[0010] The engineered RSV F protein ectodomain may be fused or conjugated to a membrane anchor and / or transmembrane domain. The transmembrane domain may comprise an RSV F protein transmembrane domain. The transmembrane domain may not comprise an RSV F protein transmembrane domain.
[0011] The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to amino acids 26-542 of any one of SEQ ID NOs: 3-54. The engineered protein may comprise an N-terminal signal sequence.
[0012] The engineered proteins may exhibit improved solubility or stability, as compared to a native RSV F in a postfusion conformation. The engineered proteins may be immunogenic and / or antigenic.
[0013] Provided herein are engineered RSV F trimers comprising three engineered proteins disclosed herein. The trimers may be stabilized in a prefusion conformation relative to a trimer of native RSV F protein subunits. The trimers may comprise at least one engineered disulfide bond between protomers.34900-4270-2501 , v. 1
[0014] Provided herein are nucleic acid molecules comprising a nucleotide sequence that encodes the amino acid sequence of an engineered protein disclosed herein. The nucleic acid molecules may further comprise a DNA expression vector. The nucleic acid molecules may be mRNAs. The nucleic acid molecules may be self-replicating RNA molecules. The nucleic acid molecules may comprise at least one chemical modification. The at least one chemical modification may be selected from the group consisting of pseudouridine, Nl-methylpseudouridine, N1 -ethylpseudouridine, N 1 -ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thio-l-methyl-l-deaza-pseudouri dine, 2-thio-l -methylpseudouridine, 2-thio-5-aza-uridine , 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-l-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-0-methyl uridine.
[0015] Provided herein are pharmaceutical compositions comprising (i) an engineered protein disclosed herein, (ii) an engineered trimer disclosed herein, or (iii) a nucleic acid molecule disclosed herein; and a pharmaceutically acceptable carrier. The pharmaceutical composition may further comprise an adjuvant. The pharmaceutical composition may further comprise a further RSV antigen. The pharmaceutical composition may be formulated within a cationic lipid nanoparticle. The pharmaceutical composition may be for use in the treatment or prevention of a RSV infection or a disease associated with RSV infection in a subject or for use in eliciting an immune response against RSV. The subject may be a mammal, such as a human.
[0016] Provided herein are methods of preventing RSV infection or a disease associated with RSV infection in a subject or eliciting an immune response in a subject or reducing RSV viral shedding in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition provided herein. The subject may be a mammal, such as a human.
[0017] Provided herein are uses of (i) an engineered protein disclosed herein, (ii) an engineered trimer disclosed herein, or (iii) a nucleic acid molecule disclosed herein; or (iv) a pharmaceutical composition provided herein, in the manufacture of a medicament for the treatment or prevention of an RSV infection or a disease associated with RSV infection.44900-4270-2501 , v. 1
[0018] Provided herein are compositions comprising (i) an engineered protein provided herein or (ii) an engineered trimer provided herein, bound to an antibody. The antibody may specifically bind to a RSV F ectodomain in the prefusion conformation.
[0019] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF DRAWINGS
[0020] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0021] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0022] FIG. 1. Analysis of thermal stability of variants of RSV F. Purified RSV F proteins, purified in parallel under identical conditions, were analyzed by differential scanning fluorimetry. DSF detects changes in fluorescence that result from exposure of previously concealed residues upon the changes of protein structure. It is predicted that the prefusion molecule will have a different DSF profile as a result of the existence of an initial melting transition where the prefusion conformation melts. Plots show the change in fluorescence with respect to temperature on the y-axis, and the temperature on the x-axis. Variants are plotted in groups, with the wildtype DSF trace reproduced in each panel for ease of comparison. Melting temperatures are provided in Table 3.
[0023] FIGS. 2A-2E. SDS-PAGE gels of variants of RSV F. (FIG. 2A) Sample 1 is RSV F base; Sample 2 is Design 1; Sample 3 is Design 2; Sample 4 is Design 3; Sample 5 is Design 4; Sample 6 is Design 5; Sample 7 is Design 6; Sample 8 is Design 7; Sample 9 is Design 8; Sample 10 is Design 9; Sample 11 is Design 10; Sample 12 is DS-Cavl. (FIG. 2B)54900-4270-2501 , v. 1Sample 1 is RSV F base; Sample 2 is Design 11; Sample 3 is Design 12; Sample 4 is Design 13; Sample 5 is Design 14; Sample 6 is Design 15; Sample 7 is Design 16; Sample 8 is Design 17; Sample 9 is Design 18; Sample 10 is Design 19; Sample 11 is Design 20; Sample 12 is DS-Cavl. (FIG. 2C) Sample 1 is RSV F base; Sample 2 is varOl having a K80F substitution; Sample 3 is var02 having K75C and S215C substitutions; Sample 4 is var03 having a N197D substitution; Sample 5 is var04 having A170C and A177C substitutions; Sample 6 is var05 having a N345 V substitution; Sample 7 is varl 0 having a S405L substitution; Sample 8 is Cav 1 having S190F and V207L substitutions. (FIG. 2D) Reducing SDS-PAGE gels show that N165D+N197D boost expression. Sample 1 is Design SMI; Sample 2 is Design SM2; Sample 3 is Design SM3; Sample 4 is Design SM4; Sample 5 is Design SM5; Sample 6 is Design SM6; Sample 7 is Design SM7; Sample 8 is RSV F base; Sample 9 is DS-Cavl. (FIG. 2E) Biological replicate of FIG. 2D.
[0024] FIGS. 3A-3B. Analysis of thermal stability of variants of RSV F having C-term variations. Purified RSV F proteins were prepared and assayed using DSF as described for FIG.1. (FIG. 3 A) Modification of DS-Cavl to the alt C-term. (FIG. 3B) Modification of designs of Table 1 to the normal C-term.
[0025] FIGS. 4A-4C. SDS-PAGE gels of variants of RSV F having C-term variations. (FIG. 4A) Sample 1 is DS-Cavl with a 10% Furin Ratio; Sample 2 is DS-Cavl alt C-term with a 10% furin ratio; Sample 3 is DS-Cavl alt C-term with a 20% furin ratio; Sample 4 is RSV Design 5 with a 10% furin ratio; Sample 5 is RSV Design 5 with a 20% furin ratio. Fold expression of Design 5 relative to DS-Cav 1 was as expected. DS-Cav 1 alt C-term had a similar A280-based yield relative to DS-Cavl, but yielded a less intense band on the gel. A higher furin ratio decreased yields by about 13-20%. (FIG. 4B) Re-run of elution gel confirming less intense band for DS-Cavl alt C-term relative to DS-Cavl. (FIG. 4C) Almost no F0 making it hard to evaluate different C-terms / Furin ratios.DETAILED DESCRIPTION
[0026] RSV remains a significant global health burden, causing severe respiratory infections in infants, elderly individuals, and immunocompromised patients. The prefusion form of the RSV F protein is the primary target of neutralizing antibodies, making it the most effective antigen for vaccine and therapeutic development.64900-4270-2501 , v. 1
[0027] Provided herein are stabilized variants of the Respiratory Syncytial Virus (RS V) fusion (F) protein, engineered to maintain the prefusion conformation for enhanced immunogenicity. Existing stabilized prefusion F proteins often suffer from suboptimal expression levels. Additionally, thermostability remains a critical challenge, as prefusion F proteins tend to degrade or transition to the postfusion form over time. These new variants incorporate stabilizing mutations that confer improved expression in mammalian cells and increased thermostability. Maintaining the prefusion conformation at higher temperatures extends shelf life and enables easier protein-based vaccine distribution, particularly in low-resource settings. These improvements make the stabilized RSV F variants useful for (1) nextgeneration RSV vaccine formulations (protein-based, mRNA-based, or nanoparticle-based), (2) monoclonal antibody discover)', and (3) diagnostic assays for RSV-specific immune responses.I. Engineered RSV F Protein Ectodomains
[0028] The RSV Fusion (F) protein is the envelope glycoprotein of respiratory syncytial viruses. The RSV F protein may be translated as a single polypeptide precursor in either a soluble (without the transmembrane domain) or membrane-bound (with the transmembrane domain) form. This polypeptide forms a trimer, which may, in some situations, be proteolytically cleaved by one or more cellular proteases at conserved furin consensus cleavage sites to yield two disulfide-bonded fragments known as the Fl (C-terminal) and F2 (N-terminal) fragments. The F2 fragment includes approximately the first 83 amino acids of the RSV F precursor. Either the uncleaved precursor protein, or a heterodimer of the cleaved F2 and Fl fragments, can form an RSV F protomer. Three such protomers assemble to form the final RSV F protein complex, which is a homotrimer of three protomers.
[0029] The RSV F protein trimer mediates fusion of viral and cellular membranes. The pre-fusion conformation of the RSV F protein trimer is highly unstable (metastable). However, once the RSV virus docks with the cell membrane, the RSV F protein trimer undergoes a series of conformational changes and transitions to a highly stable post-fusion conformation. The RSV F protein induces potent neutralizing antibodies (nAbs) that correlate with RSV protection. For example, immunization with the RSV F protein induces nAbs that are protective in humans. Several neutralizing epitopes (sites I, II and IV) are present on the post-fusion form of RSV F protein. However, incubation of human sera with the RSV F protein in its post-fusion conformation fails to deplete the majority of neutralizing activity against the F protein,74900-4270-2501 , v. 1indicating the presence of neutralizing antigenic sites unique to the pre-fusion conformation (Magro et al. 2012, PNAS 109(8): 3089). By X-ray crystallography, the epitopes recognized by palivizumab (Synagis), motavizumab (Numax), and 101F monoclonal antibody were mapped (McLellan et al, 2010, J. Virol, 84(23): 12236-441; and McLellan et al, 2010, Nat. Struct. Mol. Biol., Feb 17(2): 248-50). The structure of the F protein in its pre -fusion conformation revealed a novel neutralizing epitope - site 0 - that is only displayed in the prefusion conformation, and to which a series of antibodies bind, e.g. 5C4, that are up to 50-fold more potently neutralizing than Synagis and Numax (McLellan et al., Science 340: 1113-1117 (2013)). Accordingly, an RSV vaccine immunogen in this pre-fusion conformation and displaying site 0 could elicit effective protection.
[0030] There are various approaches for stabilizing the RSV F protein in its pre-fusion conformation, including providing specific locations within the RSV F protein that can be or should be cross-linked, and providing mutant forms of the RSV F protein that can facilitate the formation of such cross-links. Such cross-links and mutations can be used alone (e.g. in the context of a native RSV F protein), or can be used in combination with one or more other man made mutations, modifications, cross-links, or stabilization strategies. Thus, for example, the approaches described herein can be used in conjunction with the use of added foldon trimerization domains.
[0031] When reference is herein made to specific amino acid residues or specific amino acid regions in the RSV F protein by referring to their amino residue number or numbers (such as amino acid residues 75, 80, 215, or 279, for example), and unless otherwise stated, the numbering is based on the RSV amino acid sequences provided herein in the sequence listing (see, for example, SEQ ID NO: 1 or 55). However, it should be noted, and one of skill in the art will understand, that different RSV sequences may have different numbering systems, for example, if there are additional amino acid residues added or removed as compared to SEQ ID NO: 1 or 55. As such, it is to be understood that when specific amino acid residues are referred to by their number, the description is not limited to only amino acids located at precisely that numbered position when counting from the beginning of a given amino acid sequence, but rather that the equivalent / corresponding amino acid residue in any and all RSV F sequences is intended - even if that residue is not at the same precise numbered position, for example if the RSV sequence is shorter or longer than SEQ ID NO: 1 or 55, or has insertions or deletions as compared to SEQ ID NO: 1 or 55. One of skill in the art can readily determine what is the84900-4270-2501 , v. 1corresponding / equivalent amino acid position to any of the specific numbered residues recited herein, for example by aligning a given RSV F sequence to SEQ ID NO: 1 or 55 or to any of the other RSV F amino acid sequences provided herein.
[0032] Provided herein are RSV F protein and polypeptide amino acid sequences, and compositions and methods comprising such sequences. However, the RSV F protein and polypeptide amino acid sequences are not limited to the specific RSV F sequences disclosed herein. Variations, modifications and derivatives of the specific sequences provided herein are contemplated.
[0033] The engineered ectodomains or engineered proteins may include at least one mutation selected from any one of the mutations, or sets of mutations, in Table 1. The substitutions in each of the constructs described in Table 1 were introduced into a base construct having the amino acid sequence shown in SEQ ID NO: 1 (Base) or SEQ ID NO: 55. The amino acid sequence of the base construct ectodomain only (i.e., without the signal sequence or any C-terminal modifications) corresponds to amino acids 26-513 of SEQ ID NO: 1. A foldon trimerization motif of T4 fibritin (Fd) is fused to the C-terminus of the F ectodomain by a Ser-Ala-Ile-Gly linker, followed by a Thrombin protease recognition site linked by a Gly-Gly linker, a hexa-histidine tag and a Ser-Ala linked to a single Twin-Strep-tag in the base construct. This same C-terminal arrangement is used in engineered ectodomains of SEQ ID NOs: 29-54. However, the engineered ectodomains or engineered proteins of SEQ ID NO: 3-28 comprise or further comprise a C-terminal region having a foldon trimerization motif of T4 fibritin (Fd) fused to the C-terminus of the F ectodomain by a Gly-Ser linker or a Ser-Ala-Ile-Gly linker, with the Fd being followed by Gly-Arg-Ser, a HRV3C protease recognition site, a hexa-histidine tag, and a single Twin-Strep-tag at the C-terminus. The immature constructs further include a signal sequence at the N-terminus.Table 1. RSV F protein substitutions (combinations).Construct RSV substitutions SEQ ID NO: Designation (positions relative to SEQ ID NO: 1 or 55)3 K75C / S215C, N165D, Q279P, N345V, N437P 5 or 31 1 Q270E, Q279P, N345V, N437P 3 or 29 2 K75C / S215C, Q279P, Q361I 4 or 30 4 K75C / S215C, Q279P, N345V 6 or 32 5 K75C / S215C, Q279P, N437P 7 or 33 SMI K75C / S215C, Q279P, N437P. N165D, N197D 8 or 34 6 K75C / S215C, K80F, Q279P. Q361I 9 or 3594900-4270-2501 , v. 17 K80F, N197D, Q270E, N345V 10 or 36 8 K75C / S215C, Q279P, N345V, N437P 11 or 37 SM2 K75C / S215C, Q279P, N345V, N437P, Q361I 12 or 38 SM3 K75C / S215C, Q279P, N345V, N437P, Q361I, N165D, F or 39N197D9 / 16 K75C / S215C, Q270E, Q279P, N345V, N437P 14 or 40 10 K75C / S215C, Q270E, Q279P, N345V 15 or 41 11 A147P, Q279P, S443P 16 or 42 12 K75C / S215C, Q279P, T335I. N437P 17 or 43 SM4 K75C / S215C, Q279P, T335I, N437P, Q361I 18 or 44 SM5 K75C / S215C, Q279P. T335I, N437P. Q361I, N165D, 19 or 45N197D13 K75C / S215C, K80F, Q279P, N345V 20 or 46 14 K80F, Q270E, Q279P, N345V, N437P 21 or 47 15 T244V, Q284F, N345V 22 or 48 17 K75C / S215C, Q279P, T335I, N345V, N437P 23 or 49 SM6 K75C / S215C, Q279P, T335I, N345V, N437P, Q361I 24 or 50 SM7 K75C / S215C, Q279P, T335I, N345V, N437P, Q361I, 25 or 51N165D, N197D18 K75C / S215C, N345V, N388S, S405V 26 or 52 19 K80F, N197D, Q270E, Q279P, N345V, N437P 27 or 53 20 K75C / S215C, A170C / A177C, Q279P, R364Y, N437P 28 or 54 535 A147P,Q279P,S377P,N437P,S443P,K465P21 A170C,A177C,Q270E,N437P22 E60F,S150E,N380K,S55A,N227L,E487N,N175R23 G139C,Q354C24 G145C,M370C25 I57F,L252A26 K75C,S215C27 K75C,S215C,A170C,A177C,Q279P,R364Y,N437P28 K75C,S215C,K80F,Q270E,Q279P,N345V29 K75C,S215C,K80F,Q270E,Q279P,N345V,N437P30 K75C,S215C,K80F,Q279P,N345V31 K75C,S215C,K80F,Q279P,Q36lI32 K75C,S215C,K80F,Q279P,T335I33 K75C,S215C,K80F,T335I,N437P34 K75C,S215C,L141 C.T400C.A 170C.A 177C.Q279P.N437P35 K75C,S215C,L141C,T400C,Q225E,Q279P,Q284F,Q361I36 K75C,S215C,L141C,T400C,Q225E,Q284F37 K75C,S215C,L141C,T400C,Q225E,Q361I38 K75C,S215C,L141C,T400C,Q279P,Q361I39 K75C,S215C,N197D,Q270E,Q279P,N345V,N437P40 K75C,S215C,N197D,Q279P,S425L41 K75C,S215C,N345V,N388S,S405V42 K75C,S215C,N345V,N388S,S405V,S443P43 K75C,S215C,N345V,S377P,N388S,S405V,N437P44 K75C,S215C,Q225E,Q279P,Q284F,Q361I104900-4270-2501 , v. 145 K75C,S215C,Q270E,N345V46 K75C,S215C,Q270E,N437P47 K75C,S215C,Q270E,Q279P,N345V 48 K75C,S215C,Q270E,Q279P,N345V,N437P 49 K75C,S215C,Q270E,Q279P,T335I 50 K75C,S215C,Q270E,Q279P,T335I,N345V 51 K75C,S215C,Q279P,N345V52 K75C,S215C,Q279P,N345V,N437P 53 K75C,S215C,Q279P,Q361I54 K75C,S215C,Q279P,T335I,N345V 55 K75C,S215C,Q279P,T335I,N345V,N437P 56 K75C,S215C,Q279P,T335I,N437P 57 K75C,S215C,S405L,S425L58 K75C,S215C,T335I59 K80F,M97E,Q270E,N345V60 K80F,M97E,Q270E,N345V,N437P 61 K80F,M97E,Q270E,Q279P,N345V 62 K80F,M97E,Q270E,Q284F,N345V,N437P 63 K80F,N 197D,Q270E,N345 V64 K80F,N 197D,Q270E,Q279P,N345 V 65 K80F,N197D,Q270E,Q279P,N345V,N437P 66 K80F,N240Y,Q270E,Q279P,N345V 67 K80F.Q225E.Q270E.N345V68 K80F,Q270E,N345V,N437P69 K80F,Q270E,Q279P,N345V,N437P 70 K80F,Q270E,Q279P,T335I,N345V,N437P 71 K80F,Q270E,Q284F,N345V72 L141C,T400C73 L142QN371C74 L45K,K80F,Q270E,Q279P,N345V 75 L45K,K80F,Q270E,Q279P,N345V,N437P 76 L45K,L 141 C,T400C,N 165D77 L45K,L230F,Q361 ES405L78 N165D,Q225E,Q270E,N388S,N437P 79 N165D,Q270E,N345V,S405V,N437P 80 N165D,Q270E,S405V,N437P81 N197D,N345V,N388S82 N345V,N388S,S405V83 Q210V,N240Y,Q361I84 Q270E,N345V,N388S,N437P85 Q270E,Q279P,N345V,N437P86 Q270E,S377P,N437P87 S155C,S290C88 S190F,V207L89 S55C,L188C90 T103CJ148C114900-4270-2501 , v. 191 T103C,I148C,S190I,D486S 92 T335I,N345V,R364Y,S405L,S425L 93 T335I,S377P94 V207F,I79V534 A170C / A177CTable 2. RSV F single substitutions.124900-4270-2501 , v. 1Construct RSV substitutions Construct RSV substitutions Designation (positions relative to Designation (positions relative to SEQ ID NO: 1 or 55) SEQ ID NO: 1 or 55) 95 A / P102F 138 E356L 96 A107I 139 E356T 97 A107P 140 E487F 98 A107T 141 E487I 99 A10I 142 E487L 100 A10L 143 E487N 101 A122F 144 E487Q 102 A 1221 145 E487T 103 A122L 146 E60F 104 A122P 147 E60T 105 A122T 148 E92D 106 A17I 149 Fl 141 107 A17L 150 F114P 108 A23I 151 F20I 109 A241I 152 F20L 110 A241L 153 F20T 111 A241T 154 F22I 112 A47T 155 F22L 113 A490T 156 F22T 114 A543T 157 F477R 115 A571P 158 F488L 116 A8L 159 F488W 117 A8T 160 F505I 118 C211 161 F505E 119 C21L 162 F505T 120 C21P 163 F572I 121 C21T 164 F572L 122 C550L 165 F572P 123 C550T 166 F572T 124 D338F 167 G145P 125 D486N 168 G25L 126 D486S 169 G25T 127 D486T 170 G329F 128 D489F 171 G329I 129 D489H 172 G329L 130 D489L 173 G329P 131 D489S 174 G329T 132 E110T 175 G566P 133 E161P 176 G566T 134 E2F 177 I11L 135 E2I 178 I14L 136 E2L 179 I14T137 E2T180 I206LConstruct RSV substitutions Construct RSV substitutions Designation (positions relative to Designation (positions relative to SEQ ID NO: 1 or 55) SEQ ID NO: 1 or 55) 181 I214P 224 K7L 182 122 IL 225 K7T 183 I233L 226 K80F 184 126 IF 227 L111F 185 126 IL 228 Lilli 186 I266F 229 Li l IP 187 I280F 230 L111T 188 I28F 231 LI 191 189 I28L 232 L119P 190 I292F 233 L119T 191 I309L 234 L129F 192 I525F 235 L129P 193 I530F 236 L129T 194 I530T 237 L203I 195 I534F 238 L230F 196 L535P 239 L252I 197 I535T 240 L257F 198 I537T 241 L257I 199 1542T 242 L258E 200 I567F 243 L260I 201 I567L 244 L273I 202 I567P 245 L3O3F 203 I570P 246 L3O3T 204 15L 247 L3161 205 K123F 248 L316T 206 K123L 249 L373I 207 K123T 250 L3I 208 K124F 251 L3T 209 K124L 252 L410I 210 K124P 253 L456P 211 K131L 254 L45K 212 K132L 255 L4I 213 K132P 256 L4T 214 K132T 257 L538T 215 K134P 258 L539I 216 K134T 259 L539P 217 K359F 260 L541I 218 K359L 261 L546F 219 K359P 262 L546I 220 K465P 263 L546P 221 K465Q 264 L547F 222 K561P 265 L547I223 K561T266 L547T144900-4270-2501 , v. 1Construct RSV substitutions Construct RSV substitutions Designation (positions relative to Designation (positions relative to SEQ ID NO: 1 or 55) SEQ ID NO: 1 or 55) 267 L548F 310 N121F 268 L548I 311 N121I 269 L548P 312 N121L 270 L548T 313 N121P 271 L559F 314 N126P 272 L559I 315 N165D 273 L559P 316 N197D 274 L559T 317 N228I 275 L564F 318 N228L 276 L564I 319 N240T 277 L564P 320 N240Y 278 L564T 321 N254L 279 L61I 322 N254P 280 L6I 323 N254T 281 L6T 324 N345F 282 L96F 325 N345I 283 L96I 326 N345V 284 M115F 327 N371F 285 M1151 328 N371L 286 M115L 329 N371T 287 M115P 330 N380K 288 M251L 331 N437P 289 M264I 332 N568P 290 M264L 333 N568T 291 M289F 334 N569P 292 M370L 335 N569T 293 M526I 336 N574P 294 M97E 337 N67I 295 N104F 338 N67W 296 N104I 339 N9L 297 N104L 340 N9T 298 N104P 341 P101F 299 N104T 342 P101I 300 N105F 343 P101L 301 N105L 344 P112F 302 N105T 345 Pl 121 303 N116F 346 P112L 304 N116P 347 P112T 305 N116T 348 P320F 306 N120F 349 P320L 307 N120I 350 P556T 308 N120L 351 Q202K309 N120T352 Q210V154900-4270-2501 , v. 1Construct RSV substitutions Construct RSV substitutions Designation (positions relative to Designation (positions relative to SEQ ID NO: 1 or 55) SEQ ID NO: 1 or 55) 353 Q224I 396 S215F 354 Q225E 397 S215I 355 Q270E 398 S215L 356 Q279F 399 S215P 357 Q279I 400 S215T 358 Q279P 401 S238F 359 Q283A 402 S24I 360 Q283L 403 S24L 361 Q284F 404 S24T 362 Q284W 405 S287I 363 Q354I 406 S362E 364 Q354L 407 S377P 365 Q354P 408 S38F 366 Q354T 409 S398I 367 Q361F 410 S398L 368 Q361I 411 S405I 369 Q361L 412 S405L 370 Q563T 413 S405P 371 Q811 414 S405T 372 Q81L 415 S425F 373 R106F 416 S425W 374 R106I 417 S485V 375 R106L 418 S502T 376 R1081 419 S5091 377 R108L 420 S509T 378 R108P 421 S554T 379 R108T 422 S55A 380 R113F 423 S55I 381 R113I 424 S55L 382 R113L 425 S55P 383 R113T 426 S55T 384 R364F 427 S560P 385 R364W 428 S560T 386 R364Y 429 S565P 387 SI 301 430 S565T 388 S130L 431 S573T 389 S130P 432 S99I 390 S130T 433 T103F 391 S190F 434 T118F 392 SI 901 435 T118I 393 S190L 436 T118L 394 S190W 437 T118P395 S190Y438 T125P164900-4270-2501 , v. 1Construct RSV substitutions Construct RSV substitutions Designation (positions relative to Designation (positions relative to SEQ ID NO: 1 or 55) SEQ ID NO: 1 or 55) 439 T128I 482 V18T 440 T128P 483 V207F 441 T12I 484 V207L 442 T12L 485 V220I 443 T12P 486 V239T 444 T13I 487 V243F 445 T13L 488 V247P 446 T16I 489 V247T 447 T16L 490 V278F 448 T189I 491 V278I 449 T189V 492 V296I 450 T19L 493 V296L 451 T234A 494 V300I 452 T244I 495 V301I 453 T244V 496 V301L 454 T29L 497 V308T 455 T335I 498 V349I 456 T335L 499 V360I 457 T3371 500 V360L 458 T357L 501 V360P 459 T423F 502 V365I 460 T423I 503 V402F 461 T423L 504 V402L 462 T449F 505 V4061 463 T455I 506 V40T 464 T54H 507 V414L 465 T54I 508 V / M447I 466 T54L 509 V / M447T 467 T54P 510 V482L 468 T555P 511 V482T 469 T558L 512 V544L 470 T558P 513 V544T 471 T58I 514 V557P 472 T58L 515 V557T 473 T58M 516 V56I 474 V127F 517 V76I 475 VI 271 518 V76T 476 V127P 519 Y117F 477 V127T 520 Y117I 478 VI 541 521 Y117L 479 VI 641 522 Y117P 480 V164L 523 Y117T481 V18L524 Y198F174900-4270-2501 , v. 1Construct RSV substitutions Designation (positions relative to SEQ ID NO: 1 or 55) 525 Y250I526 Y33I527 Y33L528 Y33T529 Y342F530 Y457F531 Y457L532 Y457T533 Y549T535 A147P536 A170C / A177C537 G139C / Q354C538 G145C / M370C539 I57F540 I79V541 K75C / S215C542 L141C / T400C543 L142C / N371C544 L252A545 N175R546 N227L547 N388S548 S150E549 S155C / S290C550 S405V551 S425L552 S443P553 S55C / L188C554 T103C / I148C18 4900-4270-2501 , v. 1
[0034] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions Q270E, Q279P, N345V, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 3. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 3 or 29.
[0035] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, Q361I, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 4. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 4 or 30.
[0036] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55. and the amino acid substitutions K75C / S215C, N165D, Q279P, N345V, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 5. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 5 or 31.
[0037] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, N345V, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 6. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 6 or 32.
[0038] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, N437P. where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 7. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 7 or 33.
[0039] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, N437P, N165D, N197D, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least204900-4270-2501 , v. 199%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 8. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 8 or 34.
[0040] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, K80F, Q279P, Q361I, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 9. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 9 or 35.
[0041] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K80F, N197D, Q270E, N345V, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 10. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 10 or 36.
[0042] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, N345V,214900-4270-2501 , v. 1N437P. where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 11. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 11 or 37.
[0043] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, N345V, N437P, Q361I, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 12. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 12 or 38.
[0044] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, N345V, N437P, Q361I, N165D, N197D, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 13. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 13 or 39.224900-4270-2501 , v. 1
[0045] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q270E, Q279P, N345V, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 14. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 14 or 40.
[0046] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q270E, Q279P, N345V, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 15. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 15 or 41.
[0047] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions A147P, Q279P, S443P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 16. The engineered protein234900-4270-2501 , v. 1may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 16 or 42.
[0048] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, T335I, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 17. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 17 or 43.
[0049] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, T335I, N437P, Q361I, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 18. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 18 or 44.
[0050] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, T335I, N437P, Q361I, N165D, N197D, where the positions are relative to SEQ ID NO: 1 or 55. The244900-4270-2501 , v. 1engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 19. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 19 or 45.
[0051] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, K80F, Q279P, N345V, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 20. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 20 or 46.
[0052] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K80F, Q270E, Q279P, N345V, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 21. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 21 or 47.254900-4270-2501 , v. 1
[0053] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions T244V, Q284F, N345V, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 22. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 22 or 48.
[0054] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, T335I, N345V, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 23. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 23 or 49.
[0055] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, T335I, N345V, N437P, Q361I, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 24. The engineered protein may comprise an amino acid sequence having at least 90%, at least264900-4270-2501 , v. 191%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 24 or 50.
[0056] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, Q279P, T335I, N345V, N437P, Q361I, N165D, N197D, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 25. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 25 or 51.
[0057] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, N345V, N388S, S405V, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 26. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 26 or 52.
[0058] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K80F, N197D, Q270E, Q279P, N345V, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV274900-4270-2501 , v. 1F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 27. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 27 or 53.
[0059] The engineered RSV F ectodomain may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 1 or 55, and the amino acid substitutions K75C / S215C, A170C / A177C, Q279P, R364Y, N437P, where the positions are relative to SEQ ID NO: 1 or 55. The engineered RSV F ectodomain protein may comprise an amino acid sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of positions 26-513 of SEQ ID NO: 28. The engineered protein may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of positions 26-542 of SEQ ID NO: 28 or 54.II. Protein Preparation
[0060] The protein described herein may be prepared by routine methods known in the art, such as by expression in a recombinant host system using a suitable vector. Suitable recombinant host cells include, for example, insect cells, mammalian cells, avian cells, bacteria, and yeast cells. Examples of suitable insect cells include, for example, Sf9 cells, Sf21 cells, Tn5 cells, Schneider S2 cells, and HIGH FIVE cells (a clonal isolate derived from the parental Trichoplusia ni BTI-TN-5B1-4 cell line). Examples of suitable mammalian cells include Chinese hamster ovary (CHO) cells, ExpiCHO-S cells, human embryonic kidney cells (HEK293 or Expi 293 cells, typically transformed by sheared adenovirus type 5 DNA), NIH-3T3 cells, 293-T cells, Vero cells, and HeLa cells. Suitable avian cells include, for example, chicken embryonic stem cells (e.g., EBx.®. cells), chicken embryonic fibroblasts, chicken embryonic germ cells, quail fibroblasts (e.g., ELL-O), and duck cells. Suitable insect cell expression systems, such as baculovirus-vectored systems, are known to those of skill in the284900-4270-2501 , v. 1ait. Materials and methods for some mammalian cell and baculovirus / insect cell expression systems are commercially available in kit form. Avian cell expression systems are also known to those of skill in the art. Similarly, bacterial and mammalian cell expression systems are also known in the art.
[0061] A number of suitable vectors for expression of recombinant proteins in insect or mammalian cells are well-known and conventional in the art. Suitable vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, a terminator), and / or one or more translation signals; and a signal sequence or leader sequence for targeting to the secretory pathway in a selected host cell (e.g., of mammalian origin or from a heterologous mammalian or non-mammalian species). For example, for expression in insect cells a suitable baculovirus expression vector, such as PFASTBAC, is used to produce recombinant baculovirus particles. The baculovirus particles are amplified and used to infect insect cells to express recombinant protein. For expression in mammalian cells, a vector that will drive expression of the construct in the desired mammalian host cell (e.g., Chinese hamster ovary cells) is used.
[0062] The proteins can be purified using any suitable methods. For example, methods for purifying a protein by immunoaffinity chromatography are known in the art. Suitable methods for purifying desired proteins including precipitation and various types of chromatography, such as hydrophobic interaction, ion exchange, affinity, chelating and size exclusion are known in the art. Suitable purification schemes can be created using two or more of these or other suitable methods. If desired, the protein may include a “tag” that facilitates purification, such as an epitope tag or a histidine tag. Such tagged proteins can be purified, for example from conditioned media, by chelating chromatography or affinity chromatography. III. Nucleic Acids Encoding Proteins
[0063] Also provided are nucleic acid molecules that encode a protein described herein. These nucleic acid molecules include DNA, cDNA, and RNA sequences. Nucleic acid molecules that encode only the ectodomain of the protein are also contemplated. The nucleic acid molecule can be incorporated into a vector, such as an expression vector.294900-4270-2501 , v. 1
[0064] The nucleic acid may be a self-replicating RNA molecule. The nucleic acid may include a modified RNA molecule. Also provided are compositions comprising a nucleic acid described herein.IV. Formulations and Methods of Use Thereof
[0065] Provided herein are compositions and methods of using the proteins described herein, or a nucleic acid encoding the proteins described herein. For example, the proteins described herein can be delivered directly as a component of an immunogenic composition or a vaccine. Alternatively, nucleic acids that encode the proteins described herein can be administered to produce the protein or immunogenic fragment in vivo. Protein formulations, recombinant nucleic acids (e.g., DNA, RNA, mRNA, self-replicating RNA, or any variation thereof) and / or viral vectors (e.g., live, single-round, non-replicative assembled virions, or otherwise virus-like particles, or alphavirus replicon particles (VRPs)) that contain sequences encoding the proteins provided herein may be included in a composition.
[0066] Also provided are compositions including a polynucleotide that may elicit an immune response in a mammal. The polynucleotide encodes at least one polypeptide of interest, e.g., an antigen. Antigens disclosed herein may be wild type (i.e., derived from the infectious agent) or preferably modified (e.g., engineered, designed or artificial). The nucleic acid molecules described herein, specifically polynucleotides, may encode one or more engineered RSV F protein. Such peptides or polypeptides may serve as an antigen or antigenic molecule. The term “nucleic acid” includes any compound that includes a polymer of nucleotides. These polymers are referred to as “polynucleotides.” Exemplary nucleic acids or polynucleotides include, but are not limited to, ribonucleic acids (RNAs), including mRNA, and deoxyribonucleic acids (DNAs).
[0067] The composition may include DNA encoding an engineered RSV F protein or fragment thereof described herein. The composition may include RNA encoding an engineered RSV F protein or fragment thereof described herein. The composition may include an mRNA polynucleotide encoding an engineered RSV F protein or fragment thereof described herein. Such compositions may produce the appropriate protein conformation upon translation.
[0068] The composition may include at least one polynucleotide encoding two or more antigenic polypeptides or an immunogenic fragment or epitope thereof. The composition may include two or more polynucleotides encoding two or more antigenic polypeptides or304900-4270-2501 , v. 1immunogenic fragments or epitopes thereof. The one or more antigenic polypeptides may be encoded on a single polynucleotide or may be encoded individually on multiple (e.g., two or more) polynucleotides.
[0069] A composition may include (a) a polynucleotide encoding an engineered RSV F protein; and (b) a polynucleotide encoding an additional polypeptide.
[0070] An RNA polynucleotide includes any nucleic acid sequence selected from any one of the nucleic acid sequences disclosed herein, or homologs thereof having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity with a nucleic acid sequence disclosed herein. An open reading frame may be codon-optimized. A composition may include at least one RNA polynucleotide encoding at least one RSV F antigenic polypeptide or an immunogenic fragment thereof and at least one 5' terminal cap. A 5' terminal cap may be 7mG(5')ppp(5')NImpNp.
[0071] The at least one polynucleotide may have at least one chemical modification. The at least one polynucleotide may further include a second chemical modification. The polynucleotide may be RNA. The at least one polynucleotide having at least one chemical modification may have a 5' terminal cap. The at least one chemical modification may be selected from pseudouridine, N1 -methylpseudouridine, N1 -ethylpseudouridine, Nl-ethylpseudouridine, 2-thiouridine, 4' -thiouridine, 5-methylcytosine, 2-thio-l- 1 -methyl- 1-deaza-pseudouridine, 2-thio-l -methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-l -methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2'-0-methyl uridine. At least 80% (e.g., 85%, 90%, 95%, 98%, 99%, 100%) of the uracils in the open reading frame may have a chemical modification, optionally wherein the composition is formulated in a lipid nanoparticle. All of the uracils in the open reading frame may have a chemical modification. The chemical modification may be in the 5-position of the uracil. The chemical modification may be an N1 -methyl pseudouridine.
[0072] Provided herein are methods of inducing an immune response in a mammal, the methods including administering to the mammal a composition in an amount effective to induce an immune response, wherein the composition includes a polynucleotide encoding an engineered RSV F protein. The immune response may include a T cell response or a B cell314900-4270-2501 , v. 1response. The method may involve a single administration of the composition. The method may further include administering to the subject a booster dose of the composition. The composition may include a polynucleotide disclosed herein formulated in an effective amount to produce an antigen specific immune response in a mammal.
[0073] The immunogenic composition may include an adjuvant. Exemplary adjuvants to enhance effectiveness of the composition include: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with or without other specific adjuvants such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (PCT Publ. No. WO 90 / 14837), containing 5% Squalene, 0.5% TWEEN 80, and 0.5% Span 85 formulated into submicron particles using a microfluidizer, (b) SAF, containing 10% Squalane, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a sub micron emulsion or vortexed to generate a larger particle size emulsion, and (c) RIBI™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DETOX™); (3) saponin adjuvants, such as QS-21, STIMULON™ (Cambridge Bioscience, Worcester, Mass.), which may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes): (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (IFA); (5) cytokines, such as interleukins (IL-1 , IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (6) toll-like receptor agonists; and (7) other substances that act as adjuvants to enhance the effectiveness of the composition. The composition may not include an adjuvant. The composition may further include a lipid nanoparticle. The composition may be formulated in a nanoparticle. The composition may further include a cationic or polycationic compound, including protamine or other cationic peptides or proteins, such as poly-L-lysine (PLL).
[0074] Each of the immunogenic compositions discussed herein may be used alone or in combination with one or more other antigens, the latter either from the same viral pathogen or from another pathogenic source or sources. These compositions may be used for prophylactic (to prevent infection) or therapeutic (to treat disease after infection) purposes.
[0075] The composition may include a “pharmaceutically acceptable carrier,” which includes any carrier that does not itself induce the production of antibodies harmful to the324900-4270-2501 , v. 1individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as adjuvants. Furthermore, the antigen may be conjugated to a protein carrier, such as a ferritin, or a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, and etc. pathogens. For example, a disclosed engineered RS V F ectodomain can be linked to a ferritin subunit to construct a ferritin nanoparticle. Ferritin nanoparticles and their use for immunization purposes have been disclosed in the art (see, e.g., Kanekiyo et al., Nature, 499:102-106, 2013, incorporated by reference herein in its entirety). Ferritin is a globular protein that is found in all animals, insects, bacteria, and plants, and which acts primarily to control the rate and location of polynuclear FeCIIIjsOs formation through the transportation of hydrated iron ions and protons to and from a mineralized core.
[0076] The composition may include a diluent, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.
[0077] The compositions described herein may include an immunologically effective amount of the polypeptide or polynucleotide, as well as any other of the above-mentioned components, as needed. By “immunologically effective amount,” it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for eliciting an immune response. The immune response elicited may be sufficient, for example, for treatment and / or prevention and / or reduction in incidence of illness, infection or disease. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor’s assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
[0078] The composition may be administered parenterally, e.g., by injection, either subcutaneously, intramuscularly, or intradermally. The composition may be administered to the mammal by subcutaneous, intramuscular, or intradermal injection. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, nasal334900-4270-2501 , v. 1formulations, suppositories, and transdermal applications. Oral formulations may be preferred for certain viral proteins. Dosage treatment may be a single dose schedule or a multiple dose schedule. The immunogenic composition may be administered in conjunction with other immunoregulatory agents.
[0079] Also provided are methods of eliciting an immune response against RSV, comprising administering to a subject in need thereof an immunologically effective amount of the engineered RSV F protein and / or an immunogenic composition described herein, which comprises the proteins, DNA molecules, RNA molecules (e.g., self-replicating RNA molecules or niRNA molecules), or VRPs as described above. The immune response may comprise the production of neutralizing antibodies against RSV.
[0080] An immune response can comprise a humoral immune response, a cell-mediated immune response, or both. An immune response may be induced against each delivered RSV F protein. A cell-mediated immune response can comprise a Helper T-cell (Th) response, a CD8+ cytotoxic T-cell (CTL) response, or both. The immune response may comprise a humoral immune response comprising antibody-presenting B cells, and the antibodies may be neutralizing antibodies.
[0081] The polypeptide and / or immunogenic composition described herein may also elicit an effective immune response to reduce the likelihood of an RSV infection of a noninfected mammal, or to reduce symptoms following an infection or in an already infected mammal, e.g., reduce the number of outbreaks, RSV shedding, and risk of spreading the virus to other mammals.
[0082] Provided herein are methods for reducing RSV viral shedding in a mammal. Also provided are methods for reducing RSV viral titers in a mammal. The methods may reduce RSV nucleic acids in serum in a mammal. The term “viral shedding” is used herein according to its plain ordinary meaning in medicine and virology and refers to the production and release of vims from an infected cell. The vims may be released from a cell of a mammal. Vims may be released into the environment from an infected mammal. Vims may be released from a cell within a mammal.
[0083] The methods may include administering the engineered RSV F protein and / or immunogenic composition described herein to a mammal that is infected with or is at risk of an RSV infection. The reduction in RSV viral shedding in a mammal is as compared to the344900-4270-2501 , v. 1viral shedding in mammals that were not administered the engineered RSV F protein for prophylactic or therapeutic administration or those same mammals investigated prior to and post administration of the engineered RSV F protein for therapeutic administration.
[0084] The mammal may be a human. The human may be a child, such as an infant. The human may be female, including an adolescent female, a female of childbearing age, a female who is planning pregnancy, a pregnant female, and females who recently gave birth. The human may be a transplant patient or a patient awaiting a transplant.
[0085] A useful measure of antibody potency in the art is “50% neutralization titer.” Another useful measure of antibody potency is any one of the following: a “60% neutralization titer”; a “70% neutralization titer”; a “80% neutralization titer”; and a “90% neutralization titer.” To determine, for example, a 50% neutralizing titer, serum from immunized animals is diluted to assess how dilute serum can be yet retain the ability to block entry of 50% of infectious viruses into cells. For example, a titer of 700 means that serum retained the ability to neutralize 50% of infectious virus after being diluted 700-fold. Thus, higher titers indicate more potent neutralizing antibody responses. The titer may be in a range having a lower limit of about 200, about 400, about 600, about 800, about 1000, about 1500, about 2000, about 2500, about 3000, about 3500, about 4000, about 4500, about 5000, about 5500, about 6000, about 6500, or about 7000. The 50%, 60%, 70%, 80%, or 90% neutralization titer range can have an upper limit of about 400, about 600, about 800, about 1000, about 1500, about 2000, about 2500, about 3000, about 3500, about 4000, about 4500, about 5000, about 5500, about 6000, about 6500, about 7000, about 8000, about 9000, about 10000, about 1 1000, about 12000, about 13000, about 14000, about 15000, about 16000, about 17000, about 18000, about 19000, about 20000, about 21000, about 22000, about 23000, about 24000, about 25000, about 26000, about 27000, about 28000, about 29000, or about 30000. For example, the 50% neutralization titer can be about 3000 to about 6500. “About” means plus or minus 10% of the recited value. Neutralization titer can be measured as described in the specific examples, below.
[0086] An immune response can be stimulated by administering proteins, DNA molecules, RNA molecules (e.g., mRNA molecules, self-replicating RNA molecules or nucleoside modified RNA molecules), or VRPs to an individual, typically a mammal, including a human. The immune response induced may be a protective immune response, i.e., the response reduces the risk or severity of or clinical consequences of an RSV infection. Stimulating a protective immune response is particularly desirable in some populations354900-4270-2501 , v. 1particularly at risk from RSV infection and disease. For example, at-risk populations include solid organ transplant (SOT) patients, bone marrow transplant patients, and hematopoietic stem cell transplant (HSCT) patients. DNA molecules, RNA molecules, or VRPs can be administered to a transplant donor pre-transplant, or a transplant recipient pre- and / or posttransplant. Because vertical transmission from mother to child is a common source of infecting infants, administering DNA molecules, RNA molecules, or VRPs to a patient who is pregnant or can become pregnant is particularly useful.
[0087] Any suitable route of administration can be used. For example, a composition can be administered intramuscularly, intraperitoneally, subcutaneously, intradermally, or transdermally. Administration may be intra-mucosal, such as intra-orally, intra-nasally, intra-vaginally, and intra-rectally. Compositions can be administered according to any suitable schedule.
[0088] Also provided herein is a method of inhibiting RSV entry into a cell, comprising contacting the cell with the immunogenic composition described herein.
[0089] A composition may include an engineered RSV F protein described herein. A composition may include a nucleic acid molecule or vector encoding such protein. A composition may include a protein described above and a nucleic acid molecule or vector encoding such protein.
[0090] In the case that a nucleic acid molecule encoding an engineered RSV F protein is used in a pharmaceutical composition, the nucleic acid molecule may comprise or consist of deoxyribonucleotides and / or ribonucleotides, or analogs thereof, covalently linked together. A nucleic acid molecule as described herein generally contains phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages. Mixtures of naturally occurring polynucleotides and analogs can be made; alternatively, mixtures of different polynucleotide analogs, and mixtures of naturally occurring polynucleotides and analogs may be made. A nucleic acid molecule may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by nonnucleotide components. A polynucleotide may be further modified after polymerization, such364900-4270-2501 , v. 1as by conjugation with a labeling component. The term also includes both double- and singlestranded molecules. Unless otherwise specified or required, the term polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. A nucleic acid molecule is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “nucleic acid sequence” is the alphabetical representation of a nucleic acid molecule. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.
[0091] The nucleic acids of the present disclosure may comprise one or more modified nucleosides comprising a modified sugar moiety. Such compounds comprising one or more sugar-modified nucleosides may have desirable properties, such as enhanced nuclease stability or increased binding affinity with a target nucleic acid relative to an oligonucleotide comprising only nucleosides comprising naturally occurring sugar moieties. The modified sugar moieties may be substituted sugar moieties. The modified sugar moieties may be sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of substituted sugar moieties.
[0092] In some embodiments, modified sugar moieties are substituted sugar moieties comprising one or more non-bridging sugar substituent, including but not limited to substituents at the 2' and / or 5' positions. Examples of sugar substituents suitable for the 2'-position, include, but are not limited to: 2'-F, 2'-OCH3 ("OMe" or "O-methyl"), and 2'-O(CH2)2OCH3 ("MOE"). In certain embodiments, sugar substituents at the 2' position is selected from allyl, amino, azido, thio, O-allyl, O-C1-C10 alkyl, O-C1-C10 substituted alkyl; OCF3, O(CH2)2SCH3, O(CH2)2-O-N(Rm)(Rn), and O-CH2-C(=O)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C1-C10 alkyl. Examples of sugar substituents at the 5'-position, include, but are not limited to: 5'-methyl (R or S); 5'-vinyl, and 5'-methoxy. In some embodiments, substituted sugars comprise more than one nonbridging sugar substituent, for example, T-F-5'-methyl sugar moieties (see, e.g., PCT374900-4270-2501 , v. 1International Application WO 2008 / 101157, for additional 5',2'-bis substituted sugar moieties and nucleosides).
[0093] Nucleosides comprising 2'-substituted sugar moieties are referred to as 2'-substituted nucleosides. In some embodiments, a 2'-substituted nucleoside comprises a 2'-substituent group selected from halo, allyl, amino, azido, SH, CN, OCN, CF3, OCF3, O, S, or N(Rm)-alkyl; O, S, or N(Rm)-alkenyl; O, S or N(Rm)-alkynyl; O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH2)2SCH3, O(CH2)2— O— N(Rm)(Rn) or O— CH2— C(=O)— N(Rm)(Rn), where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted C1-C10 alkyl. These 2'-substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.
[0094] In some embodiments, a 2'-substituted nucleoside comprises a 2'-substituent group selected from F, NH2, N3, OCF3, O-CH3, O(CH2)3NH2, CH2— CH=CH2, O-CH2— CH=CH2, OCH2CH2OCH3, O(CH2)2SCH3, O-(CH2)2-O-N(Rm)(Rn), O(CH2)2O(CH2)2N(CH3)2, and N-substituted acetamide (O— CH2— C(=O)— N(Rm)(Rn) where each Rm and Rn is, independently, H, an amino protecting group or substituted or unsubstituted Cl -CIO alkyl.
[0095] In some embodiments, a 2'-substituted nucleoside comprises a sugar moiety comprising a 2'-substituent group selected from F, OCF3, O-CH3, OCH2CH2OCH3, O(CH2)2SCH3, O(CH2)2-O-N(CH3)2, -O(CH2)2O(CH2)2N(CH3)2, and O-CH2- C(=O)-N(H)CH3.
[0096] In some embodiments, a 2'-substituted nucleoside comprises a sugar moiety comprising a 2' -substituent group selected from F, O-CH3, and OCH2CH2OCH3.
[0097] In some embodiments, nucleosides of the present disclosure comprise one or more unmodified nucleobases. In certain embodiments, nucleosides of the present disclosure comprise one or more modified nucleobases.
[0098] In some embodiments, modified nucleobases are selected from: universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,384900-4270-2501 , v. 1including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine; 5 -hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl CH3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, 3-deazaguanine and 3 -deazaadenine, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases as defined herein. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine([5,4-b][l,4]benzoxazin-2(3H)-one), phenothiazine cytidine (lH-pyrimido[5,4-b][l,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g., 9-(2-aminoethoxy)-H-pyrimido[5,4-13][l,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido|3',2':4,5|pyrrolo|2,3-d|pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Patent 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed by Englisch et al., 1991; and those disclosed by Sanghvi, Y. S., 1993.
[0099] Representative United States Patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, U.S. Patents 3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, each of which is herein incorporated by reference in its entirety.
[0100] Additional modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. For example, one additional modification of the ligand conjugated oligonucleotides of the present disclosure involves chemically linking to the394900-4270-2501 , v. 1oligonucleotide one or more additional non-ligand moieties or conjugates which enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., 1989), cholic acid (Manoharan et al., 1994), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al., 1992; Manoharan et al., 1993), a thiocholesterol (Oberhauser et al., 1992), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., 1991; Kabanov et al., 1990; Svinarchuk et al., 1993), a phospholipid, e.g., di-hexadecyl-rac -glycerol or triethylammonium l,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., 1995; Shea et al., 1990), a poly amine or a polyethylene glycol chain (Manoharan et al., 1995), or adamantane acetic acid (Manoharan et al., 1995), a palmityl moiety (Mishra et al., 1995), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., 1996). In some aspects, a nucleic acid molecule encoding an engineered RS V F protein is a modified RNA, such as, for example, a modified mRNA. Modified (m)RNA contemplates certain chemical modifications that confer increased stability and low immunogenicity to mRNAs, thereby facilitating expression of therapeutically important proteins. For instance, Nl-methyl-pseudouridine (Nlm'P) outperforms several other nucleoside modifications and their combinations in terms of translation capacity. In some embodiments, the (m)RNA molecules used herein may have the uracils replaced with psuedouracils such as l-methyl-3'-pseudouridylyl bases. In some embodiments, some of the uracils are replaced, but in other embodiments, all of the uracils have been replaced. The (m)RNA may comprise a 5’ cap, a 5’ UTR element, an optionally codon optimized open reading frame, a 3’ UTR element, and a poly(A) sequence and / or a polyadenylation signal.
[0101] The nucleic acid molecule, whether native or modified, may be delivered as a naked nucleic acid molecule or in a delivery vehicle, such as a lipid nanoparticle. A lipid nanoparticle may comprise one or more nucleic acids present in a weight ratio to the lipid nanoparticles from about 5: 1 to about 1 : 100. In some embodiments, the weight ratio of nucleic acid to lipid nanoparticles is from about 5:1, 2.5:1, 1:1, 1:5, 1:10, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:60, 1:70, 1:80, 1:90, or 1:100, or any value derivable therein.
[0102] In some embodiments, the lipid nanoparticles used herein may contain one, two, three, four, five, six, seven, eight, nine, or ten lipids. These lipids may include triglycerides, phospholipids, steroids or sterols, PEGylated lipids, or a group with an ionizable group such as an alkyl amine and one or more hydrophobic groups such as C6 or greater alkyl groups.404900-4270-2501 , v. 1
[0103] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more steroid or a steroid derivative. In some embodiments, the steroid or steroid derivative comprises any steroid or steroid derivative. As used herein, in some embodiments, the term “steroid” is a class of compounds with a four ring 17 carbon cyclic structure which can further comprises one or more substitutions including alkyl groups, alkoxy groups, hydroxy groups, oxo groups, acyl groups, or a double bond between two or more carbon atoms.
[0104] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more PEGylated lipids (or PEG lipids). In some embodiments, the present disclosure comprises using any lipid to which a PEG group has been attached. In some embodiments, the PEG lipid is a diglyceride which also comprises a PEG chain attached to the glycerol group. In other embodiments, the PEG lipid is a compound which contains one or more C6-C24 long chain alkyl or alkenyl group or a C6-C24 fatty acid group attached to a linker group with a PEG chain. Some non-limiting examples of a PEG lipid includes a PEG modified phosphatidylethanolamine and phosphatidic acid, a PEG ceramide conjugated, PEG modified dialkylamines and PEG modified l,2-diacyloxypropan-3-amines, PEG modified di acylglycerols and dialkylglycerols. In some embodiments, PEG modified diastearoylphosphatidylethanolamine or PEG modified dimyristoyl-sn-glycerol. In some embodiments, the PEG modification is measured by the molecular weight of PEG component of the lipid. In some embodiments, the PEG modification has a molecular weight from about 100 to about 15,000. In some embodiments, the molecular weight is from about 200 to about 500, from about 400 to about 5,000, from about 500 to about 3,000, or from about 1,200 to about 3,000. The molecular weight of the PEG modification is from about 100, 200, 400, 500, 600, 800, 1,000, 1,250, 1,500, 1,750, 2,000, 2,250. 2,500, 2.750, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 12,500, to about 15,000. Some non-limiting examples of lipids that may be used in the present disclosure are taught by U.S. Patent 5,820,873, WO 2010 / 141069, or U.S. Patent 8,450,298, which is incorporated herein by reference.
[0105] In some aspects of the present disclosure, the lipid nanoparticles are mixed with one or more phospholipids. In some embodiments, any lipid which also comprises a phosphate group. In some embodiments, the phospholipid is a structure which contains one or two long chain C6-C24 alkyl or alkenyl groups, a glycerol or a sphingosine, one or two phosphate groups, and, optionally, a small organic molecule. In some embodiments, the small organic414900-4270-2501 , v. 1molecule is an amino acid, a sugar, or an amino substituted alkoxy group, such as choline or ethanolamine. In some embodiments, the phospholipid is a phosphatidylcholine. In some embodiments, the phospholipid is distearoylphosphatidylcholine or dioleoylphosphatidylethanolamine. In some embodiments, other zwitterionic lipids are used, where zwitterionic lipid defines lipid and lipid-like molecules with both a positive charge and a negative charge.
[0106] In some aspects of the present disclosure, lipid nanoparticle containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable, are provided. In some embodiments, the cationic ionizable lipids contain one or more groups which is protonated at physiological pH but may deprotonated and has no charge at a pH above 8, 9, 10, 11, or 12. The ionizable cationic group may contain one or more protonatable amines which are able to form a cationic group at physiological pH. The cationic ionizable lipid compound may also further comprise one or more lipid components such as two or more fatty acids with C6-C24 alkyl or alkenyl carbon groups. These lipid groups may be attached through an ester linkage or may be further added through a Michael addition to a sulfur atom. In some embodiments, these compounds may be a dendrimer, a dendron, a polymer, or a combination thereof.
[0107] In some aspects of the present disclosure, composition containing compounds containing lipophilic and cationic components, wherein the cationic component is ionizable, are provided. In some embodiments, ionizable cationic lipids refer to lipid and lipid-like molecules with nitrogen atoms that can acquire charge (pKa). These lipids may be known in the literature as cationic lipids. These molecules with amino groups typically have between 2 and 6 hydrophobic chains, often alkyl or alkenyl such as C6-C24 alkyl or alkenyl groups, but may have at least 1 or more than 6 tails.
[0108] In some embodiments, the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w / w to about 50% w / w, from about 0.25% w / w to about 25% w / w, from about 0.5% w / w to about 20% w / w, from about 1% w / w to about 15% w / w, from about 2% w / w to about 10% w / w, from about 2% w / w to about 5% w / w, or from about 6% w / w to about 10% w / w. In some embodiments, the amount of the lipid nanoparticle with the nucleic acid molecule encapsulated in the pharmaceutical composition is from about 0.1% w / w, 0.25% w / w, 0.5% w / w, 1% w / w, 2.5% w / w, 5% w / w, 7.5% w / w, 10% w / w, 15% w / w, 20% w / w, 25% w / w, 30% w / w, 35% w / w, 40%424900-4270-2501 , v. 1w / w, 45% w / w, 50% w / w, 55% w / w, 60% w / w, 65% w / w, 70% w / w, 75% w / w, 80% w / w, 85% w / w, 90% w / w, to about 95% w / w, or any range derivable therein.
[0109] In some aspects, the present disclosure comprises one or more sugars formulated into pharmaceutical compositions. In some embodiments, the sugars used herein are saccharides. These saccharides may be used to act as a lyoprotectant that protects the pharmaceutical composition from destabilization during the drying process. These water-soluble excipients include carbohydrates or saccharides such as disaccharides such as sucrose, trehalose, or lactose, a trisaccharide such as fructose, glucose, galactose comprising raffinose, polysaccharides such as starches or cellulose, or a sugar alcohol such as xylitol, sorbitol, or mannitol. In some embodiments, these excipients are solid at room temperature. Some nonlimiting examples of sugar alcohols include erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotritol, maltotetraitol, or a polyglycitol.
[0110] In some embodiments, the amount of the sugar in the pharmaceutical composition is from about 25% w / w to about 98% w / w, 40% w / w to about 95% w / w, 50% w / w to about 90% w / w, 50% w / w to about 70% w / w, or from about 80% w / w to about 90% w / w. In some embodiments, the amount of the sugar in the pharmaceutical composition is from about 10% w / w, 15% w / w, 20% w / w, 25% w / w, 30% w / w, 35% w / w, 40% w / w, 45% w / w, 50% w / w, 52.5% w / w, 55% w / w, 57.5% w / w, 60% w / w, 62.5% w / w, 65% w / w, 67.5% w / w, 70% w / w, 75% w / w, 80% w / w, 82.5% w / w, 85% w / w, 87.5% w / w, 90% w / w, to about 95% w / w, or any range derivable therein.
[0111] In some embodiments , the pharmaceutically acceptable polymer is a copolymer. The pharmaceutically acceptable polymer may further comprise one, two, three, four, five, or six subunits of discrete different types of polymer subunits. These polymer subunits may include polyoxypropylene, polyoxyethylene, or a similar subunit. In particular, the pharmaceutically acceptable polymer may comprise at least one hydrophobic subunit and at least one hydrophilic subunit. In particular, the copolymer may have hydrophilic subunits on each side of a hydrophobic unit. The copolymer may have a hydrophilic subunit that is polyoxyethylene and a hydrophobic subunit that is polyoxypropylene.
[0112] In some embodiments, expression cassettes are employed to express an RSV F protein, either for subsequent purification and delivery to a cell / subject, or for use directly in a434900-4270-2501 , v. 1viral-based delivery approach. Provided herein are expression vectors which contain one or more nucleic acids encoding an RSV F protein.
[0113] Expression requires that appropriate signals be provided in the vectors and include various regulatory elements such as enhancers / promoters from both viral and mammalian sources that drive expression of the engineered RSV F protein in cells. Throughout this application, the term “expression cassette” is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed and translated, i.e., is under the control of a promoter. A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrase “under transcriptional control” means that the promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. An “expression vector” is meant to include expression cassettes comprised in a genetic construct that is capable of replication, and thus including one or more of origins of replication, transcription termination signals, poly-A regions, selectable markers, and multipurpose cloning sites.
[0114] The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the EBV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.
[0115] At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the S V40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.
[0116] Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements444900-4270-2501 , v. 1downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.
[0117] Viral promoters, such as the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter, the Rous sarcoma vims long terminal repeat, rat insulin promoter and glyceraldehyde-3 -phosphate dehydrogenase can be used to obtain high-level expression of the coding sequence of interest. The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of a coding sequence of interest is contemplated as well, provided that the levels of expression are sufficient for a given purpose. By employing a promoter with well-known properties, the level and pattern of expression of the protein of interest following transfection or transformation can be optimized. Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the gene product.
[0118] Enhancers are genetic elements that increase transcription from a promoter located at a distant position on the same molecule of DNA. Enhancers are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins. The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities. Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization.
[0119] Below is a list of promoters / enhancers and inducible promoters / enhancers that could be used in combination with the nucleic acid encoding a gene of interest in an expression construct. Additionally, any promoter / enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of the gene. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial454900-4270-2501 , v. 1polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
[0120] The promoter and / or enhancer may be, for example, immunoglobulin light chain, immunoglobulin heavy chain, T-cell receptor, HLA DQ a and / or DQ |3, P-interferon, interleukin-2, interleukin-2 receptor, MHC class II 5, MHC class II HLA-Dra, [3-Actin, muscle creatine kinase (MCK), prealbumin (transthyretin), elastase I, metallothionein (MTII), collagenase, albumin, a-fetoprotein, t-globin, [ -globin, c-fos, c-HA-ra.v, insulin, neural cell adhesion molecule (NCAM), ai-antitrypain, H2B (TH2B) histone, mouse and / or type I collagen, glucose-regulated proteins (GRP94 and GRP78), rat growth hormone, human serum amyloid A (SAA), troponin I (TN I), platelet-derived growth factor (PDGF), SV40, polyoma, retroviruses, papilloma virus, hepatitis B virus, human immunodeficiency virus, cytomegalovirus (CMV), and gibbon ape leukemia virus.
[0121] Where a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. Any polyadenylation sequence may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.
[0122] There are a number of ways in which expression vectors may be introduced into cells. The expression construct may comprise a virus or engineered construct derived from a viral genome. The ability of certain viruses to enter cells via receptor-mediated endocytosis, to integrate into host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer of foreign genes into mammalian cells. These have a relatively low capacity for foreign DNA sequences and have a restricted host spectrum. Furthermore, their oncogenic potential and cytopathic effects in permissive cells raise safety concerns. They can accommodate only up to 8 kB of foreign genetic material but can be readily introduced in a variety of cell lines and laboratory animals.
[0123] One method for in vivo delivery involves the use of an adenovirus expression vector. “Adenovirus expression vector” is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to express an464900-4270-2501 , v. 1engineered RSV F protein that has been cloned therein. In this context, expression does not require that the gene product be synthesized.
[0124] The expression vector comprises a genetically engineered form of adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kB, linear, double-stranded DNA vims, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kB. In contrast to retro vims, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.
[0125] Adenovims is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are cis elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The El region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off. The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5’-tripartite leader (TPL) sequence which makes them preferred mRNAs for translation. In one system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of vims from an individual plaque and examine its genomic structure.
[0126] Generation and propagation of the current adenovims vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively474900-4270-2501 , v. 1expresses El proteins. Since the E3 region is dispensable from the adenovirus genome, the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the El, the D3 or both regions. In nature, adenovirus can package approximately 105% of the wild-type genome, providing capacity for about 2 extra kb of DNA. Combined with the approximately 5.5 kb of DNA that is replaceable in the El and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kb, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the El-deleted virus is incomplete.
[0127] Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the preferred helper cell line is 293.
[0128] The adenoviruses of the disclosure are replication defective, or at least conditionally replication defective. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is one exemplary starting material that may be used to obtain the conditional replication-defective adenovirus vector for use in the present disclosure.
[0129] Other viral vectors may be employed as expression constructs in the present disclosure. Vectors derived from viruses such as vaccinia virus, adeno-associated virus (AAV) and herpesviruses may be employed. They offer several attractive features for various mammalian cells.
[0130] The vector may be an AAV vector. AAV is a small virus that infects humans and some other primate species. AAV is not currently known to cause disease. The virus causes a very mild immune response, lending further support to its apparent lack of pathogenicity. In many cases, AAV vectors integrate into the host cell genome, which can be important for certain applications, but can also have unwanted consequences. Gene therapy vectors using AAV can infect both dividing and quiescent cells and persist in an extrachromosomal state without integrating into the genome of the host cell, although in the native virus some484900-4270-2501 , v. 1integration of virally carried genes into the host genome does occur. These features make AAV a very attractive candidate for creating viral vectors for gene therapy, and for the creation of isogenic human disease models. Recent human clinical trials using AAV for gene therapy in the retina have shown promise. AAV belongs to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. The vims is a small (20 nm) replication-defective, nonenveloped vims.
[0131] The AAV genome is built of single-stranded deoxyribonucleic acid (ssDNA), either positive- or negative-sensed, which is about 4.7 kilobase long. The genome comprises inverted terminal repeats (ITRs) at both ends of the DNA strand, and two open reading frames (ORFs): rep and cap. The former is composed of four overlapping genes encoding Rep proteins required for the AAV life cycle, and the latter contains overlapping nucleotide sequences of capsid proteins: VP1, VP2 and VP3, which interact together to form a capsid of an icosahedral symmetry.
[0132] With regard to gene therapy, ITRs seem to be the only sequences required in cis next to the therapeutic gene: stmctural (cap) and packaging (rep) proteins can be delivered in trans. With this assumption many methods were established for efficient production of recombinant AAV (rAAV) vectors containing a reporter or therapeutic gene. However, it was also published that the ITRs are not the only elements required in cis for the effective replication and encapsidation. A few research groups have identified a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene. CARE was shown to augment the replication and encapsidation when present in cis.
[0133] In some aspects, the present disclosure provides pharmaceutical compositions that contain one or more salts. The salts may be an inorganic potassium or sodium salt such as potassium chloride, sodium chloride, potassium phosphate dibasic, potassium phosphate monobasic, sodium phosphate dibasic, or sodium phosphate monobasic. The pharmaceutical composition may comprise one or more phosphate salts such to generate a phosphate buffer solution. The phosphate buffer solution may be comprise each of the phosphates to buffer a solution to a pH from about 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0, or any range derivable therein.
[0134] In some aspects, the present disclosure comprises one or more excipients formulated into pharmaceutical compositions. An “excipient” refers to pharmaceutically494900-4270-2501 , v. 1acceptable carriers that are relatively inert substances used to facilitate administration or delivery of an API into a subject or used to facilitate processing of an API into drug formulations that can be used pharmaceutically for delivery to the site of action in a subject. Furthermore, these compounds may be used as diluents in order to obtain a dosage that can be readily measured or administered to a patient. Non-limiting examples of excipients include polymers, stabilizing agents, surfactants, surface modifiers, solubility enhancers, buffers, encapsulating agents, antioxidants, preservatives, nonionic wetting or clarifying agents, viscosity increasing agents, and absorption-enhancing agents.
[0135] The term “pharmaceutically acceptable" may mean approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and can preferably include an adjuvant. Water is a particular carrier when the pharmaceutical composition is administered by injections, such an intramuscular injection. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
[0136] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard earners such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.” Such compositions will contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with a suitable amount of earner so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, or delivered by mechanical ventilation.504900-4270-2501 , v. 1
[0137] Engineered proteins or nucleic acids encoding engineered proteins of the present disclosure, as described herein, can be formulated for parenteral administration, e.g., formulated for injection via the intradermal, intravenous, intramuscular, subcutaneous, intra-tumoral or even intraperitoneal routes. The formulation could alternatively be administered by a topical route directly to the mucosa, for example by nasal drops, inhalation, or by nebulizer. Pharmaceutically acceptable salts include the acid salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
[0138] Generally, the ingredients of compositions of the disclosure are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
[0139] The compositions of the disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
[0140] Dosage can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunization schedule and / or in a booster immunization schedule. In a multiple dose schedule the various doses may be given by the same or different routes. Multiple doses will typically be administered at least 1 week apart (e.g., about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).514900-4270-2501 , v. 1
[0141] The compositions disclosed herein may be used to treat both children and adults. Thus, a human subject may be less than 1 year old, 1-5 years old, 5-16 years old, 16-55 years old, 55-65 years old, or at least 65 years old.
[0142] Preferred routes of administration include, but are not limited to, intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, and intraocular injection. Particularly preferred routes of administration include intramuscular, intradermal and subcutaneous injection.V. Antibodies and Diagnostic Uses
[0143] The polypeptides described above may be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected animal or mammal (e.g., mouse, rabbit, goat, guinea pig, horse, etc.) is immunized with an immunogenic polypeptide bearing an RSV epitope(s). Serum from the immunized animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an RSV epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.
[0144] Monoclonal antibodies directed against RSV epitopes can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA or viruses known to immortalize B lymphocytes, such as EBV. Alternatively, the general methodology for making monoclonal antibodies by single B cell sorting is known. B cells from an immunized or otherwise convalescent human or animal are sorted utilizing the RSV epitope of interest as a “bait” and epitopes that are not desirable as a negative selection. Isolated B cells are single cell sequenced and the antibody encoding genes are subcloned into an expression vector. Antibodies are subsequently expressed from the expression vector. Panels of monoclonal antibodies produced against RSV epitopes can be screened for various properties; i.e., for isotype, epitope affinity, neutralizing potency against the virus, etc.
[0145] Antibodies, both monoclonal and polyclonal, which are directed against RSV epitopes are particularly useful in diagnosis, and those which are neutralizing are useful in524900-4270-2501 , v. 1passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise antiidiotype antibodies.
[0146] Both the polypeptides which react immunologically with serum containing RS V antibodies, and the antibodies raised against these polypeptides, may be useful in immunoassays to detect the presence of RSV antibodies, or the presence of the virus, in biological samples, including for example, blood or serum samples. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. For example, the immunoassay may utilize the polypeptide having the sequence set forth in any one of SEQ ID NOs: 3-28.
[0147] Alternatively, the immunoassay may use a combination of viral antigens derived from the polypeptides described herein. It may use, for example, a monoclonal antibody directed towards at least one polypeptide described herein, a combination of monoclonal antibodies directed towards the polypeptides described herein, monoclonal antibodies directed towards different viral antigens, polyclonal antibodies directed towards the polypeptides described herein, or polyclonal antibodies directed towards different viral antigens. Protocols may be based, for example, upon competition, or direct reaction, or may be sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.
[0148] Kits suitable for immunodiagnostics and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the engineered RSV F proteins containing RSV epitopes or antibodies directed against epitopes in suitable containers, along with the remaining reagents and materials required for the conduct of the assay, as well as a suitable set of assay instructions.
[0149] The polynucleotide probes can also be packaged into diagnostic kits. Diagnostic kits include the probe DNA, which may be labeled; alternatively, the probe DNA may be unlabeled and the ingredients for labeling may be included in the kit. The kit may also contain534900-4270-2501 , v. 1other suitably packaged reagents and materials needed for the particular hybridization protocol, for example, standards, as well as instructions for conducting the test.VI. Immunodetection Methods
[0150] The present disclosure concerns immunodetection methods for binding, purifying, removing, quantifying and otherwise generally detecting RSV F protein. While such methods can be applied in a traditional sense, another use will be in quality control and monitoring of vaccine stocks, where antibodies according to the present disclosure can be used to assess the amount or integrity (i.e., long term stability) of antigens. Alternatively, the methods may be used to screen various antibodies for appropriate / desired reactivity profiles.
[0151] Some immunodetection methods include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, and Western blot to mention a few. In particular, a competitive assay for the detection and quantitation of RSV F protein also is provided. The steps of various useful immunodetection methods have been described in the scientific literature, such as, e.g., Doolittle and Ben-Zeev (1999), Gulbis and Galand (1993), De Jager et al. (1993), and Nakamura et al. (1987). In general, the immunobinding methods include obtaining a sample suspected of containing RSV F protein, and contacting the sample with a first antibody in accordance with the present disclosure, as the case may be, under conditions effective to allow the formation of immunocomplexes.
[0152] These methods include methods for detecting or purifying RSV F protein from a sample. The antibody will preferably be linked to a solid support, such as in the form of a column matrix, and the sample suspected of containing the RSV F protein will be applied to the immobilized antibody. The unwanted components will be washed from the column, leaving the RSV F protein-expressing cells immunocomplexed to the immobilized antibody, which is then collected by removing the organism or antigen from the column.
[0153] The immunobinding methods also include methods for detecting and quantifying the amount of RSV F protein or related components in a sample and the detection and quantification of any immune complexes formed during the binding process. Here, one would obtain a sample suspected of containing RSV F protein and contact the sample with an antibody that binds RSV F protein or components thereof, followed by detecting and quantifying the amount of immune complexes formed under the specific conditions. In terms544900-4270-2501 , v. 1of antigen detection, the biological sample analyzed may be any sample that is suspected of containing RSV F protein, such as a tissue section or specimen, a homogenized tissue extract, a biological fluid (e.g., a nasal swab), including blood and serum, or a secretion, such as feces or urine.
[0154] Contacting the chosen biological sample with the antibody under effective conditions and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time long enough for the antibodies to form immune complexes with, i.e., to bind to RSV F protein. After this time, the sampleantibody composition, such as a tissue section, ELISA plate, dot blot or Western blot, will generally be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected.
[0155] In general, the detection of immunocomplex formation is well known in the art and may be achieved through the application of numerous approaches. These methods are generally based upon the detection of a label or marker, such as any of those radioactive, fluorescent, biological and enzymatic tags. Patents concerning the use of such labels include U.S. Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241. Of course, one may find additional advantages through the use of a secondary binding ligand such as a second antibody and / or a biotin / avidin ligand binding arrangement, as is known in the art.
[0156] The antibody employed in the detection may itself be linked to a detectable label, wherein one would then simply detect this label, thereby allowing the amount of the primary immune complexes in the composition to be determined. Alternatively, the first antibody that becomes bound within the primary immune complexes may be detected by means of a second binding ligand that has binding affinity for the antibody. In these cases, the second binding ligand may be linked to a detectable label. The second binding ligand is itself often an antibody, which may thus be termed a “secondary” antibody. The primary immune complexes are contacted with the labeled, secondary binding ligand, or antibody, under effective conditions and for a period of time sufficient to allow the formation of secondary immune complexes. The secondary immune complexes are then generally washed to remove any non-specifically bound labeled secondary antibodies or ligands, and the remaining label in the secondary immune complexes is then detected.554900-4270-2501 , v. 1
[0157] Further methods include the detection of primary immune complexes by a two-step approach. A second binding ligand, such as an antibody that has binding affinity for the antibody, is used to form secondary immune complexes, as described above. After washing, the secondary immune complexes are contacted with a third binding ligand or antibody that has binding affinity for the second antibody, again under effective conditions and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody is linked to a detectable label, allowing detection of the tertiary immune complexes thus formed. This system may provide for signal amplification if this is desired.
[0158] One method of immunodetection uses two different antibodies. A first biotinylated antibody is used to detect the target antigen, and a second antibody is then used to detect the biotin attached to the complexed biotin. In that method, the sample to be tested is first incubated in a solution containing the first step antibody. If the target antigen is present, some of the antibody binds to the antigen to form a biotinylated antibody / antigen complex. The antibody / antigen complex is then amplified by incubation in successive solutions of streptavidin (or avidin), biotinylated DNA, and / or complementary biotinylated DNA, with each step adding additional biotin sites to the antibody / antigen complex. The amplification steps are repeated until a suitable level of amplification is achieved, at which point the sample is incubated in a solution containing the second step antibody against biotin. This second step antibody is labeled, as for example with an enzyme that can be used to detect the presence of the antibody / antigen complex by histoenzymology using a chromogen substrate. With suitable amplification, a conjugate can be produced which is macroscopically visible.
[0159] Another known method of immunodetection takes advantage of the immuno-PCR (Polymerase Chain Reaction) methodology. The PCR method is similar to the Cantor method up to the incubation with biotinylated DNA, however, instead of using multiple rounds of streptavidin and biotinylated DNA incubation, the DNA / biotin / streptavidin / antibody complex is washed out with a low pH or high salt buffer that releases the antibody. The resulting wash solution is then used to cany out a PCR reaction with suitable primers with appropriate controls. At least in theory, the enomrous amplification capability and specificity of PCR can be utilized to detect a single antigen molecule.564900-4270-2501 , v. 1A. ELISAs
[0160] Immunoassays, in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art. Immunohistochemical detection using tissue sections is also particularly useful. However, it will be readily appreciated that detection is not limited to such techniques, and western blotting, dot blotting, FACS analyses, and the like may also be used.
[0161] In one exemplary ELISA, the antibodies of the disclosure are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the RS V F protein is added to the wells. After binding and washing to remove non-specifically bound immune complexes, the bound antigen may be detected. Detection may be achieved by the addition of another anti-RSV F protein antibody that is linked to a detectable label. This type of ELISA is a simple “sandwich ELISA.” Detection may also be achieved by the addition of a second anti-RSV F protein antibody, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label.
[0162] In another exemplary ELISA, the samples suspected of containing the RSV F protein (e.g., potentially infected cells) are immobilized onto the well surface and then contacted with the anti-RSV F protein antibodies of the disclosure. After binding and washing to remove non-specifically bound immune complexes, the bound anti-RSV F protein antibodies are detected. Where the initial anti-RSV F protein antibodies are linked to a detectable label, the immune complexes may be detected directly. Again, the immune complexes may be detected using a second antibody that has binding affinity for the first anti-RSV F protein antibody, with the second antibody being linked to a detectable label.
[0163] Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating and binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described below.
[0164] In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period of hours. The wells of the plate will then be washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then “coated” with a574900-4270-2501 , v. 1nonspecific protein that is antigenically neutral with regard to the test antisera. These include bovine serum albumin (BSA), casein or solutions of milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface.
[0165] In ELIS As, it is probably more customary to use a secondary or tertiary detection means rather than a direct procedure. Thus, after binding of a protein or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the biological sample to be tested under conditions effective to allow immune complex (antigen / antibody) formation. Detection of the immune complex then requires a labeled secondary binding ligand or antibody, and a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or a third binding ligand.
[0166] “Under conditions effective to allow immune complex (antigen / antibody) formation” means that the conditions preferably include diluting the antigens and / or antibodies with solutions such as BSA, bovine gamma globulin (BGG) or phosphate buffered saline (PBS)ZTween, wherein the Tween is frequently Tween 20. These added agents also tend to assist in the reduction of nonspecific background.
[0167] The “suitable” conditions also mean that the incubation is at a temperature or for a period of time sufficient to allow effective binding. Incubation steps are typically from about 1 to 2 to 4 hours or so, at temperatures preferably on the order of 25°C to 27°C, or may be overnight at about 4°C or so.
[0168] Following all incubation steps in an ELISA, the contacted surface is washed so as to remove non-complexed material. A preferred washing procedure includes washing with a solution such as PBS / Tween, or borate buffer. Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.
[0169] To provide a detecting means, the second or third antibody will have an associated label to allow detection. Preferably, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact or incubate the first and second immune complex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a584900-4270-2501 , v. 1period of time and under conditions that favor the development of further immune complex formation (e.g., incubation for 2 hours at room temperature in a PBS -containing solution such as PBS-Tween).
[0170] After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS), or H2O2, in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generated, e.g., using a visible spectra spectrophotometer.B. Western Blot
[0171] The Western blot (alternatively, protein immunoblot) is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D structure of the protein (native / non-denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) using antibodies specific to the target protein.
[0172] Samples may be taken from whole tissue or from cell culture. In most cases, solid tissues are first broken down mechanically using a blender (for larger sample volumes), using a homogenizer (smaller volumes), or by sonication. Cells may also be broken open by one of the above mechanical methods. Assorted detergents, salts, and buffers may be employed to encourage lysis of cells and to solubilize proteins. Protease and phosphatase inhibitors are often added to prevent the digestion of the sample by its own enzymes. Tissue preparation is often done at cold temperatures to avoid protein denaturing.
[0173] The proteins of the sample are separated using gel electrophoresis. Separation of proteins may be by isoelectric point (pl), molecular weight, electric charge, or a combination of these factors. The nature of the separation depends on the treatment of the sample and the nature of the gel. This is a very useful way to determine a protein. It is also possible to use a two-dimensional (2-D) gel which spreads the proteins from a single sample out in two dimensions. Proteins are separated according to isoelectric point (pH at which they have neutral net charge) in the first dimension, and according to their molecular weight in the second dimension.594900-4270-2501 , v. 1
[0174] In order to make the proteins accessible to antibody detection, they are moved from within the gel onto a membrane made of nitrocellulose or polyvinylidene difluoride (PVDF). The membrane is placed on top of the gel, and a stack of filter papers placed on top of that. The entire stack is placed in a buffer solution which moves up the paper by capillary action, bringing the proteins with it. Another method for transferring the proteins is called electroblotting and uses an electric current to pull proteins from the gel into the PVDF or nitrocellulose membrane. The proteins move from within the gel onto the membrane while maintaining the organization they had within the gel. As a result of this blotting process, the proteins are exposed on a thin surface layer for detection (see below). Both varieties of membrane are chosen for their non-specific protein binding properties (i.e., binds all proteins equally well). Protein binding is based upon hydrophobic interactions, as well as charged interactions between the membrane and protein. Nitrocellulose membranes are cheaper than PVDF, but are far more fragile and do not stand up well to repeated probing. The uniformity and overall effectiveness of transfer of protein from the gel to the membrane can be checked by staining the membrane with Coomassie Brilliant Blue or Ponceau S dyes. Once transferred, proteins are detected using labeled primary antibodies, or unlabeled primary antibodies followed by indirect detection using labeled protein A or secondary labeled antibodies binding to the Fc region of the primary antibodies.C. Immunohistochemistry
[0175] The antibodies of the present disclosure may also be used in conjunction with both fresh-frozen and / or formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC). The method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors, and is well known to those of skill in the art (Brown et al., 1990; Abbondanzo et al., 1990; Allred et al., 1990).
[0176] Briefly, frozen-sections may be prepared by rehydrating 50 ng of frozen “pulverized” tissue at room temperature in phosphate buffered saline (PBS) in small plastic capsules; pelleting the particles by centrifugation; resuspending them in a viscous embedding medium (OCT); inverting the capsule and / or pelleting again by centrifugation; snap-freezing in -70°C isopentane; cutting the plastic capsule and / or removing the frozen cylinder of tissue; securing the tissue cylinder on a cryostat microtome chuck; and / or cutting 25-50 serial sections604900-4270-2501 , v. 1from the capsule. Alternatively, whole frozen tissue samples may be used for serial section cuttings.
[0177] Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube; pelleting; resuspending in 10% formalin for 4 hours fixation; washing / pelleting; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue / agar block from the tube; infiltrating and / or embedding the block in paraffin; and / or cutting up to 50 serial permanent sections. Again, whole tissue samples may be substituted.D. Immunodetection Kits
[0178] Provided herein are immunodetection kits for use with the immunodetection methods described above. As the antibodies may be used to detect RSV F protein, the antibodies may be included in the kit. The immunodetection kits will thus comprise, in suitable container means, a first antibody that binds to an RSV F protein, and optionally an immunodetection reagent.
[0179] The antibody may be pre-bound to a solid support, such as a column matrix and / or well of a microtitre plate. The immunodetection reagents of the kit may take any one of a variety of forms, including those detectable labels that are associated with or linked to the given antibody. Detectable labels that are associated with or attached to a secondary binding ligand are also contemplated. Exemplary secondary ligands are those secondary antibodies that have binding affinity for the first antibody.
[0180] Further suitable immunodetection reagents for use in the present kits include the two-component reagent that comprises a secondary antibody that has binding affinity for the first antibody, along with a third antibody that has binding affinity for the second antibody, the third antibody being linked to a detectable label. As noted above, a number of exemplary labels are known in the art and all such labels may be employed in connection with the present disclosure.
[0181] The kits may further comprise a suitably aliquoted composition of RSV F protein, whether labeled or unlabeled, as may be used to prepare a standard curve for a detection assay. The kits may contain antibody-label conjugates either in fully conjugated form, in the614900-4270-2501 , v. 1form of intermediates, or as separate moieties to be conjugated by the user of the kit. The components of the kits may be packaged either in aqueous media or in lyophilized form.
[0182] The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which the antibody may be placed, or preferably, suitably aliquoted. The kits of the present disclosure will also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.E. Flow Cytometry and FACS
[0183] The antibodies of the present disclosure may also be used in flow cytometry or FACS. Flow cytometry' is a laser- or impedance-based technology employed in many detection assays, including cell counting, cell sorting, biomarker detection and protein engineering. The technology suspends cells in a stream of fluid and passing them through an electronic detection apparatus, which allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second. Flow cytometry is routinely used in the diagnosis of disorders, especially blood cancers, but has many other applications in basic research, clinical practice and clinical trials.
[0184] Fluorescence-activated cell sorting (FACS) is a specialized type of cytometry. It provides a method for sorting a heterogenous mixture of biological cells into two or more containers, one cell at a time, based on the specific light scattering and fluorescent characteristics of each cell. In general, the technology involves a cell suspension entrained in the center of a narrow, rapidly flowing stream of liquid. The flow is arranged so that there is a large separation between cells relative to their diameter. A vibrating mechanism causes the stream of cells to break into individual droplets. Just before the stream breaks into droplets, the flow passes through a fluorescence measuring station where the fluorescence of each cell is measured. An electrical charging ring is placed just at the point where the stream breaks into droplets. A charge is placed on the ring based immediately prior to fluorescence intensity being measured, and the opposite charge is trapped on the droplet as it breaks form the stream. The charged droplets then fall through an electrostatic deflection system that diverts droplets into containers based upon their charge.624900-4270-2501 , v. 1
[0185] To be used in flow cytometry or FACS, the antibodies of the present disclosure may be labeled with fluorophores and then allowed to bind to the cells of interest, which are analyzed in a flow cytometer or sorted by a FACS machine.VII. Definitions
[0186] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and / or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise. Also, the use of the term “portion” can include part of a moiety or the entire moiety.
[0187] As used herein, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one.
[0188] The term “about” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of up to ±10% from the specified value. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the disclosed subject matter. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contain certain errors634900-4270-2501 , v. 1necessarily resulting from the standard deviation found in their respective testing measurements.
[0189] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and / or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is therefore well below 0.05%, preferably below 0.01 %. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
[0190] As used herein, a “prefusion conformation” refers to a structural conformation adopted by the polypeptide that differs from the RSV F postfusion conformation at least in terms of molecular dimensions or three-dimensional coordinates of some or all of the molecule. The prefusion conformation refers to a structural conformation adopted by RSV F prior to triggering of the fusogenic event that leads to transition of F to the postfusion conformation. Isolating RSV F in a stable prefusion conformation may be useful in informing and directing development of improved vaccines and immunogenic compositions to address the important public health problem of RSV infections. A prefusion conformation may be a conformation that can bind to a prefusion-specific antibody. An engineered prefusion RSV F may exhibit a prefusion stability that is increased at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% relative to an RSV F sequence having at least 90% identity to wildtype RSV F (e.g., positions 26-513 of SEQ ID NO: 1 or 55). The prefusion stability of an engineered RSV F may be assessed by DSF or DLS, preferably DSF.
[0191] The term “antibody” refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to the target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An “antibody” is a species of an antigen binding protein. An intact antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camelids which can comprise only heavy chains. Antibodies can be derived solely from a single source, or can be “chimeric,” that is, different portions of the antibody can be derived from two different antibodies as described further below. The antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by644900-4270-2501 , v. 1enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term “antibody” includes, in addition to antibodies comprising two full-length heavy chains and two full-length light chains, derivatives, variants, fragments, and muteins thereof, examples of which are described below. Furthermore, unless explicitly excluded, antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof, respectively.
[0192] An antibody that “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope. For example, the RSV F protein specific antibodies of the present disclosure are specific to RSV F protein. The antibody that binds to RSV F protein may have a dissociation constant (Kd) of ^=100 nM, ^10 nM, ^1 nM, ^0.1 nM, ^0.01 nM, or 1=0.001 nM (e.g., 10“8M or less, e.g., from 10“8M to 10“13M, e.g., from 10-9M to 10-13M).
[0193] The term “epitope” as used herein refers to the specific group of atoms or amino acids on an antigen to which an antibody binds. The epitope can be either linear epitope or a conformational epitope. A linear epitope is formed by a continuous sequence of amino acids from the antigen and interacts with an antibody based on their primary structure. A conformational epitope, on the other hand, is composed of discontinuous sections of the antigen’s amino acid sequence and interacts with the antibody based on the 3D structure of the antigen. In general, an epitope is approximately five or six amino acids in length. Two antibodies may bind the same epitope within an antigen if they exhibit competitive binding for the antigen.
[0194] The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology,654900-4270-2501 , v. 1(Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073.
[0195] In calculating percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, NucL Acid Res. 12:387: Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1 / 10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 forthe PAM 250 comparison matrix; Henikoff etal., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) may be also used by the algorithm.
[0196] Examples of parameters that can be employed in determining percent identity for polypeptides or nucleotide sequences using the GAP program can be found in Needleman etal., 1970, J. Mol. Biol. 48:443-453.
[0197] Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 or other number of contiguous amino acids of the target polypeptide.664900-4270-2501 , v. 1
[0198] The term “link” as used herein refers to the association via intramolecular interaction, e.g., covalent bonds, metallic bonds, and / or ionic bonding, or inter-molecular interaction, e.g., hydrogen bond or noncovalent bonds.
[0019] The term “operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. Thus, a given signal peptide that is operably linked to a polypeptide directs the secretion of the polypeptide from a cell. In the case of a promoter, a promoter that is operably linked to a coding sequence will direct the expression of the coding sequence. The promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.
[0200] The use of the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” As used herein “another” may mean at least a second or more.
[0201] The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and intemucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate and phosphoroamidate.
[0202] The terms “polypeptide” or “protein” means a macromolecule having the amino acid sequence of a native protein, that is, a protein produced by a naturally-occurring and nonrecombinant cell; or it is produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and / or substitutions of one or more amino acids of the native sequence. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of a corresponding naturally occurring amino acid and polymers. The terms “polypeptide” and “protein” specifically encompass RSV F protein binding proteins,674900-4270-2501 , v. 1antibodies, or sequences that have deletions from, additions to, and / or substitutions of one or more amino acid of antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and / or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. Fragments may be about five to 500 amino acids long. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long. Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of an RSV F protein-binding antibody, useful fragments include but are not limited to a CDR region, a variable domain of a heavy and / or light chain, a portion of an antibody chain or just its variable region including two CDRs, and the like.
[0203] The pharmaceutically acceptable carriers are conventional. Remington’s Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the fusion proteins herein disclosed. In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch or magnesium stearate. In addition to biologically- neutral earners, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
[0204] As used herein, the term “subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate). A human includes pre-and post-natal forms. A subject may be a human being. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” A subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.684900-4270-2501 , v. 1
[0205] The term “therapeutically effective amount” or “effective dosage” as used herein refers to the dosage or concentration of a drug effective to treat a disease or condition. For example, with regard to the use of the monoclonal antibodies or antigen-binding fragments thereof disclosed herein to treat viral infection.
[0206] “Treating” or “treatment” of a condition or infection as used herein includes preventing or alleviating a condition or infection, slowing the onset or rate of development of a condition or infection, reducing the risk of developing a condition or infection, preventing or delaying the development of symptoms associated with a condition or infection, reducing or ending symptoms associated with a condition or infection, generating a complete or partial regression of a condition or infection, mitigating a condition or infection, curing a condition or infection, or some combination thereof.
[0207] “Prevention” or “preventing” includes: (1) inhibiting the onset of a disease / infection in a subject or patient which may be at risk and / or predisposed to the disease / infection but does not yet experience or display any or all of the pathology or symptomatology of the disease / infection, and / or (2) slowing the onset of the pathology or symptomatology of a disease / infection in a subject or patient which may be at risk and / or predisposed to the disease / infection but does not yet experience or display any or all of the pathology or symptomatology of the disease / infection.
[0208] As used herein, a “vector” refers to a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in the host cell, such as an origin of replication. A vector may also include one or more therapeutic genes and / or selectable marker genes and other genetic elements known in the art. A vector can transduce, transform or infect a cell, thereby causing the cell to express nucleic acids and / or proteins other than those native to the cell. A vector optionally includes materials to aid in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein coating or the like.VIII. Examples
[0209] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for694900-4270-2501 , v. 1its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.Example 1
[0210] The base constructs used for the RSV F variants contained the RSV F ectodomain followed by a C-terminal foldon-Thrombin-6XHis-TwinStrep tag. “Foldon” refers the trimerization motif from T4 fibritin. Base construct zero (also referred to as: Base construct 0, Base 0; SEQ ID NO: 1) contains the full RSV F ectodomain including the signal sequence (residues 1-513). Base construct 1 (Ds-Cavl; SEQ ID NO: 2) contains S155C, S290C, S190F, V207L substitutions.
[0211] Using structure-based design, substitutions that were aimed at favoring the stability of the prefusion structure were introduced into the base construct. Pairs of core-facing residues less than 5 A apart were replaced with aromatic sidechains or pairs of aromatic and positively charged sidechains to favor pi-pi or pi-cation interactions, respectively. Alternatively, residues were replaced with extended or bulkier hydrophobic sidechains in efforts to fill pre-existing internal cavities. Disulfide bonds were designed to increase overall stability or prevent formation of the postfusion conformation. The charged or polar substitutions were aimed to establish hydrogen bonds or salt bridges with the native residues that were predicted to be within 4.0 A. Exemplary combinations of substitutions are provided in Table 1.
[0212] Plasmids encoding RSV F variants were transiently co-transfected with a Furin protease encoding plasmid at a 10:1 ratio into FreeStyle293F cells (Thermo Fisher) using polyethyleneimine, with 5 pM kifunensine being added 3 h post-transfection. Cultures were grown for 4-6 days, and culture supernatant was separated via centrifugation and passage through a 0.22 pm filter. Protein was purified from supernatants using StrepTactin resin (IBA). RSV F variants were further purified by size-exclusion chromatography (SEC) using a Superose 6 10 / 300 column (GE Healthcare) in a buffer composed of 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaNs. For initial purification and characterization, single-substitution and combinatorial variants were purified from 40 mL cultures. The expression levels were704900-4270-2501 , v. 1determined by SDS-PAGE (FIG. 2). Yield and fold expression data based on absorbance at 280 nm (A280) are provided in Table 3.
[0213] To evaluate the effect of various substitutions on thermostability, differential scanning fluorimetry (DSF) was performed on various constructs (see FIG. 1). Purified RSV F variants at a final concentration ranging from 0.3- luM were mixed with a final concentration of 30X SYPRO Orange Protein Gel Stain (ThermoFisher) in a white, opaque 96-well plate (VWR). A Roche Eight Cycler 480 II was then used to measure the solutions by continuous fluorescence scanning (Zex=465 nm, Xem=580 nm). The temperature ramp rate was 4.4 °C / minute for a temperature range of 25 °C to 95 °C. Data were plotted as the negative first derivative as a function of temperature (-dF / dT). Thermostability is a valuable assay in assisting in determining if RSV F designs are existing in the prefusion conformation because the prefusion form should a different thermostable profile compared to the postfusion form. Theoretically, because prefusion is considered a meta-stable state, meaning it exists in that form prior to collapse to a more thermodynamically stable postfusion form, its melting temperature should be lower than the postfusion form. Indeed, some screened designs show altered DSF melting profiles consistent with the development of an early melting peak. Melting temperature data are provided in Table 3.
[0214] Each of the designs provided in Table 1 were made with a modified sequence at the C-terminal portion of the ectodomain. In particular, these designs include a foldon trimerization motif of T4 fibritin (Fd) fused to the C-terminus of the F ectodomain by a Gly-Ser linker or a Ser-Ala-Ile-Gly linker, with the Fd being followed by Gly-Arg-Ser, a HRV3C protease recognition site, a hexa-histidine tag, and a single Twin-Strep-tag at the C-terminus. To evaluate the effect of this modification, the C-terminal portion of DS-Cavl was modified to include a foldon trimerization motif of T4 fibritin (Fd) fused to the C-terminus of the F ectodomain by a Gly-Ser linker or a Ser-Ala-Ile-Gly linker, with the Fd being followed by Gly-Arg-Ser, a HRV3C protease recognition site, a hexa-histidine tag, and a single Twin-Strep-tag at the C-terminus. These were indicated as having the “alt C-term”. As shown in FIG. 3 A, this caused a reduction in Tm relative to DS-Cavl of 6.3°C. As a control, design 5, which also has the alt C-term, was tested and showed the expected boost in Tm of 8°C relative to DS-Cavl. Next, certain of the designs from Table 1 were modified to include the same C-terminal sequence as DS-Cavl, i.e., a foldon trimerization motif of T4 fibritin (Fd) that is fused to the C-terminus of the F ectodomain by a Ser-Ala-Ile-Gly linker, followed by a Thrombin protease714900-4270-2501 , v. 1recognition site linked by a Gly-Gly linker, a hexa-histidine tag and a Ser- Ala linked to a single Twin-Strep-tag (see SEQ ID NOs: 29-54). These were indicated as having the “normal C-term”. The expression levels were determined by SDS-PAGE (FIG. 4). Yield and fold expression data based on absorbance at 280 nm (A280) are provided in Table 4. As shown in FIG. 3B, these modifications generally led to even higher boosts in Tm relative to DS-Cavl .724900-4270-2501 , v. 1Table 3ADesign Mutations Approximate Fold Expression Fold Expression Expression Score Tm Tm Boost over Yield (mg / L) Rel. Base Rel. DS-Cavl (Fold Expression Rel. (°C) DS-Cavl (°C)Base+DS-Cavl)1 Q270E, Q279P, N345V, 0.46 0.51 0.16 0.25 63.3 9.15 N437P2 K75C / S215C, Q279P, 4.24 4.69 1.49 2.26 61.6 7.43 Q361I3 K75C / S215C, N165D, 6.03 6.68 2.12 3.22 63.3 9.15 Q279P, N345V, N437P4 K75C / S215C. Q279P, 0.93 1.03 0.33 0.49 61.0 6.86 N345V5 K75C / S215C. Q279P, 7.85 8.70 2.76 4.19 62.2 8.00 N437PSMI K75C / S215C. Q279P, 3.68 12.19 2.73 4.46 61.6 7.4 N437P, N165D, N197D6 K75C / S215C, K80F, 2.69 2.98 0.94 1.43 62.7 8.57 Q279P, Q361I7 K80F, N197D, Q270E, 0.06 0.06 0.02 0.03 53.0 -2.29 N345V8 K75C / S215C, Q279P, 2.47 2.74 0.87 1.32 63.9 9.72 N345V, N437PSM2 K75C / S215C, Q279P, 0.71 2.35 0.53 0.86 64.7 10.6 N345V, N437P, Q361ISM3 K75C / S215C, Q279P, 1.16 3.86 0.86 1.41 65.0 10.9 N345V, N437P, Q361I,N165D, N197D9 K75C / S215C, Q270E, 0.78 0.86 0.27 0.41 63.9 9.72 Q279P, N345V, N437P10 K75C / S215C, Q270E, 0.13 0.15 0.05 0.07 61.0 5.72Q279P, N345V11 A147P, Q279P, S443P 0.25 0.15 0.07 0.09 57.6 3.43 12 K75C / S215C, Q279P, 2.02 1.20 0.56 0.76 64.7 10.57 T335I, N437PSM4 K75C / S215C, Q279P, 0.53 1.76 0.39 0.64 65.6 11.4 T335I, N437P, Q361ISM5 K75C / S215C, Q279P, 1.33 4.41 0.99 1.61 65.6 11.4 T335I, N437P, Q361I,N165D, N197D13 K75C / S215C, K80F, 0.34 0.20 0.10 0.13 61.0 6.86 Q279P, N345V14 K80F, Q270E, Q279P, 0.09 0.05 0.02 0.03 62.1 6.86 N345V, N437P15 T244V, Q284F, N345V 0.05 0.03 0.01 0.02 N / A N / A 17 K75C / S215C, Q279P, 0.17 0.10 0.05 0.07 65.6 10.30 T335I, N345V, N437PSM6 K75C / S215C, Q279P, 0.14 0.47 0.11 0.17 66.7 12.6 T335I, N345V, N437P,Q361ISM7 K75C / S215C, Q279P, 0.23 0.76 0.17 0.28 66.7 12.6 T335I, N345V, N437P,Q361I, N165D, N197D18 K75C / S215C, N345V, 0.84 0.50 0.23 0.32 54.7 0.57 N388S, S405V19 K80F, N197D, Q270E, 0.07 0.04 0.02 0.03 62.7 7.44 Q279P, N345V, N437P20 K75C / S215C, A170C- 2.29 1.36 0.64 0.87 61.6 7.43 A177C, Q279P, R364Y,N437PK80F 3.3 1.04K75C, S215C 5.3 1.69N197D 2.8 0.89744900-4270-2501, v 1A170C, A177C 1.3 0.42N345V 0.7 0.22S405L 2.6 0.82S190F, V207L 12.0 3.82Table 3B - Biological replicate of Table 3ADes Mutations Approximate Yield Fold Expression Rel. Fold Expression Rel. Expression Score ign (mg / L) Base DS-Cavl (Fold Expression Rel. Base+DS-Cavl) SM K75C / S215C, Q279P, N437P, N165D, 3.58 2.58 2.34 2.45 1 N197DSM K75C / S215C, Q279P, N345V, N437P, 0.52 0.38 0.34 0.36 2 Q361ISM K75C / S215C, Q279P, N345V, N437P, 1.17 0.85 0.77 0.80 3 Q361I, N165D, N197DSM K75C / S215C, Q279P, T335I, N437P, 0.45 0.33 0.30 0.31 4 Q361ISM K75C / S215C, Q279P, T335I, N437P, 1.21 0.87 0.79 0.83 5 Q361I, N165D, N197DSM K75C / S215C, Q279P, T335I, N345V, 0.07 0.05 0.05 0.05 6 N437P, Q361ISM K75C / S215C, Q279P, T335I, N345V, 0.18 0.13 0.11 0.127 N437P, Q3611, N165D, N197D754900-4270-2501, v 1Table 4Design Furin Ratio Approximate Yield Fold Expression Tm (°C) Tm Boost over DS- (mg / L) Rel. DS-Cavl Cavl (°C) DS-Cavl 10% 0.79 1 53.6 0.0 DS-Cavl alt C-term 10% 0.82 1.04 47.3 -6.3 DS-Cavl alt C-term 20% 0.66 0.84Design 5 10% 2.18 2.77 61.6 8.0Design 5 20% 1.91 2.42764900-4270-2501, v 1
[0215] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.774900-4270-2501 , v. 1REFERENCESThe following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.US20170298101A1US10858400B2US20230265127A1US10017543B2US20230218738A1US20220332766A1WO2014 / 160463W02015 / 013551DOI: 10.1126 / science.l243283DOI: 10.1038 / ncomms9143DOI: 10.1126 / scitranslmed.ade6422784900-4270-2501 , v. 1
Claims
CLAIMS1. An engineered protein comprising an engineered Respiratory Syncytial Virus (RSV) Fusion (F) protein ectodomain comprising a sequence having at least 90% identity to amino acids 26-513 of SEQ ID NO: 1 or SEQ ID NO: 55, said engineered ectodomain comprising a single substitution or a set of substitutions selected from Tables 1 or 2.
2. The engineered protein of claim 1 , wherein the RSV F protein ectodomain comprises K75C / S215C, N165D, Q279P, N345V, and N437P substitutions and optionally comprises an amino acid sequence at least 95% identical to amino acids 26-513 of SEQ ID NO: 5an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 26-513 of SEQ ID NO: 1 or SEQ ID NO: 55.
3. The engineered protein of claim 1 or 2, wherein the RSV F protein ectodomain comprises an amino acid sequence having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 26-513 of one of SEQ ID NOs: 3-28.
4. The engineered protein of any one of claims 1-3, wherein the engineered protein does not comprise the cytoplasmic tail of RSV F.
5. The engineered protein of any one of claims 1-4, wherein the engineered RSV F protein ectodomain is fused or conjugated to a trimerization domain, optionally wherein the trimerization domain comprises a T4 fibritin trimerization domain; a GCN4 domain; a 4J4A domain; a two-helix bundle comprising complementary first heptad repeat (HR1) and second heptad repeat (HR2) regions; or a combination thereof.
6. The engineered protein of claim 5, wherein the trimerization domain is fused to the C-terminus of the ectodomain via a linker.
7. The engineered protein of any one of claims 1-6, wherein the engineered RSV F protein ectodomain is fused or conjugated to a membrane anchor and / or transmembrane domain.
8. The engineered protein of claim 7, wherein the transmembrane domain comprises an RSV F protein transmembrane domain.794900-4270-2501 , v.
19. The engineered protein of claim 7, wherein the transmembrane domain does not comprise an RSV F protein transmembrane domain.
10. The engineered protein of any one of claims 1-9, which comprises a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acids 26-542 of any one of SEQ ID NOs: 3-54.
11. The engineered protein of any one of claims 1-10, wherein the RSV F protein ectodomain comprises an elimination of the furin cleavage site.
12. The engineered protein of any one of claims 1-11, comprising an N-terminal signal sequence.
13. An engineered RS V F protein trimer comprising three engineered proteins according to any one of claims 1-12.
14. A nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence of the engineered protein of any one of claims 1-12, optionally wherein the nucleic acid molecule further comprises a DNA expression vector, an mRNA, or a self-replicating RNA molecule.
15. The nucleic acid molecule of claim 14, which further comprises at least one chemical modification, optionally wherein the at least one chemical modification is selected from the group consisting of pseudouridine, N1 -methylpseudouridine, N1 -ethylpseudouridine, Nl-ethylpseudouridine, 2-thiouridine, 4' -thiouridine, 5-methylcytosine, 2-thio-l-methyl-l-deaza-pseudouri dine, 2-thio-l-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy -pseudouridine, 4-thio-l-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-0-methyl uridine.
16. A pharmaceutical composition comprising (i) the engineered protein of any one of claims 1-12, (ii) the engineered trimer of 13, or (iii) the nucleic acid molecule of claim 14 or 15; and a pharmaceutically acceptable carrier, optionally further comprising an adjuvant.804900-4270-2501 , v.
117. The pharmaceutical composition of claim 16, wherein the composition is formulated within a cationic lipid nanoparticle.
18. A method of treating or preventing Respiratory Syncytial Virus (RSV) infection or a disease associated with RSV infection in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16 or 17.
19. A method of eliciting an immune response in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16 or 17.
20. A method for reducing RSV viral shedding in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16 or 17.814900-4270-2501 , v. 1
